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Lung cancer is one of the most devastating diseases with a 5-year survival rate of 17 %. The 
reason for this poor prognosis is that the disease is often detected at a late stages because of 
the reliance on low accuracy/low sensitivity diagnostic techniques such as, X-rays and CT-
scans. These techniques give non-specific answers as to the exact causes of a patient’s 
symptoms; in that they can detect if an abnormality is present, but not what it is. There is a 
clear need for new diagnostic techniques which can deduce the presence of lung cancer in an 
efficient and cost-effective manner. Molecular imaging with targeted fluorescent probes has 
been demonstrated as a highly sensitive approach for visualising active diseases, with several 
probes currently in clinical trials. To image lung cancer, this work aims to recreate the concept 
of antibody directed enzyme prodrug therapy (ADEPT) except replacing the enzyme catalyst 
with a palladium catalyst. These antibody-catalyst conjugates would be able to catalyst de-
propargylation reactions of protected fluorophores such as Rhodamine 110 and 
Dichlorofluorescein, thus giving a mechanism to “switch on” fluorescent signals that can be 
used to image the location of cancer cells. 
To deliver this, a library of palladium-N-heterocyclic carbene complexes were created through 
novel resin-based synthetic methodologies, enabling rapid multi-reaction synthesis with one 
purification step. All the catalysts contained moieties that could subsequently be used for 
bioconjugation, therefore the catalysts developed could be attached to targeting molecules 
such as antibodies. The catalysts were shown to be biocompatible and catalytically active in 
biological environments, with a lead catalyst shown to activate a prodrug in a 3D cancer 
spheroid model.  
Subsequently, the synthesised Pd-catalysts were for the first time, conjugated onto antibodies 
in a world first discovery. The Pd-antibody conjugates were shown to catalyse the activation 
of a fluorescent reporter, and optimisation of conjugates was performed with different Pd-
loading and spacers trialled. These Pd-antibodies represent a huge step forward and could be 
used to ultimately image cancer cells in vitro and in vivo. In the future, these biologically 
targeted Pd-catalyst conjugates could highlight tumour margins by activating a range of 
florescent probes or activate prodrugs to help kill the tumour at the same time, representing a 





Lung cancer is one of the deadliest non-infectious diseases known, and the main cause of the 
high mortality rate is that patients do not “identify” they have the disease until it has progressed 
beyond effective medical intervention. This occurs because the disease initially presents 
indiscernible symptoms, which are often attributed to lesser illnesses such as the common cold 
and flu. In addition, doctors struggle to identify lung cancer at an early stage is because the 
techniques used to image the chest, such as X-rays, don’t have the specificity required to 
correctly give a definitive answer.  
New technologies that use visible light would drastically improve lung cancer diagnosis. As 
such, fluorescent molecules are currently being developed for clinical use and offer an 
innovative way for doctors to identify a range of diseases with a much higher degree of 
confidence. If these fluorescent molecules can be “switched on” by design, they could be used 
in vivo from non-fluorescent precursors, to “tag” cancers, without harming the rest of the body. 
The element palladium can catalyse reactions which do not naturally occur in the body, and 
therefore be used to switch on the fluorescent reporters when desired. 
As a part of the immune system, antibodies can distinguish between healthy and non-healthy 
tissue. By attaching palladium to them, the antibody will transport the palladium to the site of 
the cancerous tumour where it can catalyse non-natural reactions. By also delivering the 
relevant starting materials to the same site as the catalyst, it is possible to generate a fluorescent 
reporter which would identify cancerous lesions in the lung much more easily. The following 
work shows how such results can be achieved and looks to explore how palladium can also be 
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Chapter 1 Introduction 
1.1 Lung cancer  
1.1.1 General 
Cancer is one of the most devastating diseases worldwide with an estimated 18.4 million 
people affected by the disease in 2018.1 It is believed that 1 in 2 people worldwide will get 
cancer at some stage in their lifetimes and this represents an enormous burden on health 
services around the world. Cancer is a particularly “interesting” disease as it normally 
originates from cells within the host through an accumulation of genetic mutations (Figure 
1.1). The mutations can originate from several different sources including environmental 
chemicals, UV radiation, DNA replication errors and pathogens. Mutations that cause cancer 
lead to one of two outcomes: pathways which control and regulate cellular growth and 
proliferation are damaged, or pathways which activate cellular death are inhibited. Either way, 
the cells become “immortalised” meaning that the processes which normally regulate cellular 
division don’t function as they should, and growth is uninhibited and uncontrolled. This often 
causes disease as uncontrolled growth leads to tumour masses that can protrude into other 
organs and thereby damaging their role/function. 
 
Figure 1.1 Genetic mutations in cells resulting in cancer. Each star in the nucleus represents a new 
mutation. Any single mutation by itself can be enough to cause a cell to become cancerous, however 
each additional mutation increases the likelihood of this occurring. Cells can also carry mutations and 
not be cancerous. 
Lung cancer is particularly problematic disease representing 11 % of all cancer diagnosies,1 
while accounting for 20 % of cancer deaths;1,2 higher than any other type. Lung cancer tumours 




categorised using the internationally recognised tumour, node, metastasises (TNM) system. 
“T” is the primary tumour size, “N” indicates if local lymph nodes have been involved with 
the cancer and “M” indicates if there is metastatic spread to other organs (Table 1.1).3 There 
are two sub classes of lung cancer, the first is non-small cell lung cancer (NSCLC) which 
accounts for 85 % of cases and the second, small cell lung cancer (SCLC) which accounts for 
15 % of cases. 
Table 1.1 Lung cancer TNM stages and descriptions 
Stage  Description 
I Tumours are up to 5 cm in diameter with no involvement of lymph nodes 
or metastasis. 
II Tumours are up to 7 cm in diameter and with some involvement of regional 
lymph nodes. 
III Tumours over 7 cm in diameter with severe regional lymph node 
involvement. Secondary tumours may have begun to be established in other 
organs. 
IV Distant metastasis of other organs including liver, bone, brain, adrenal 
glands and kidneys with secondary tumours of over 5 cm. 
 
Lung cancer has a 90 % association with tobacco smoking4 (meaning 9 out of 10 patients are 
either themselves smokers or are exposed regularly to second-hand smoke) because of this, 
lung cancer is generally more prevalent in western countries. Smoking is also common in both 
India and China where, it’s estimated that there could be more than 400 million smokers in the 
two countries combined; denoting that this is a global health issue. Moreover, as developing 
countries become wealthier, tobacco smoking is adopted as a “luxury” habit. This is leading 
to a rise in lung cancer rates in continents such as Africa and the rest of Asia. However, the 
number of cases in “never smokers” is also rising, stemming from people who live in cities 
where pollution and smog contribute to lung cancer development.5 
The overall 5-year survival rate for lung cancer is 17 %. Breaking this down there are some 




stage IV so, most patients are diagnosed when the cancer has already spread to lymph nodes 
and other organs. Secondly, the 5-year survival rate for patients diagnosed at stage III is 20 % 
and for patients at stage IV it is 5 %. However, the survival rate for stage I can be as high as 
80 % and for stage II 50 %, so there is a clear correlation between the stage of diagnosis and 
the 5-year survival rate. There are important underlying reasons for these statistics, and they’re 
rooted in the diagnosis procedures and treatment options. 
1.1.2 Diagnosis and treatment 
Diagnosing lung cancer is not easy. The first challenge clinicians face is getting patients 
suspected of having the disease to be seen by their doctor. One of the issues here is that many 
of the symptoms that are presented by lung cancer in the early stages are non-specific. They 
include: 
• Chesty cough  
• Persistent chest infections  
• Fatigue 
• Loss of appetite 
Naturally these symptoms could also be caused by all sorts of other issues such as chronic 
obstructive pulmonary disorder (COPD), a bacterial infection, asthma or fibrosis. These 
symptoms also overlap with viral infections such as the common cold. As such, many patients 
do not recognise their own level of risk and do not refer themselves to their local doctor. 
During the later stages of disease progression when it becomes more serious, more obvious 
symptoms occurs such as:  
• Coughing up blood 
• Fainting  
• Wheezing  
• Chest and shoulder pain.  
Because of this overall ambiguity, many patient referrals occur once the disease has progressed 
to its more serious stages (stages III and IV). 
Once patients have been referred to lung respiratory specialists, they will often have an X-ray 
or CT scan to image the chest (Figure 1.2).6 However, images created only show if there are 




of imaging is twofold: assess the extension of disease, and target the area for further biological 
sampling. During the CT scan, it is pertinent to scan other areas of the body (such as the brain) 
for metastases as they’re highly common and many patients will present metastases. Iodinated 
contrast agents can also be used to assess invasion to local lymph nodes. In parallel to this, a 
biopsy to extract a sample of the abnormal tissue identified and then characterise the disease 
state is often performed. Once a biopsy has been taken (normally a needle biopsy), histology 
will be used to confirm the presence of cancer or other disease and in certain cases DNA 
screening to identify genotypes. 
 
Figure 1.2 CT scan of chest cavity with suspected lung tumour (red box). Image adapted from 
reference 6.  
Once lung cancer has been diagnosed the next step is to decide on a treatment plan. The best 
method to treat cancer is to remove all the cancerous cells via surgery. The presence of cancer 
cells in the area surrounding the resected tumour is one of the best indicators for tumour 
recurrence and poor patient survival. Quite often during surgery, surgeons will use the “index 
finger rule” to determine tumour margins. They will use one index finger width around the 
identified tumour and remove that tissue too. This is carried out, because it is difficult to 
identify tumour margins and thus certainty of where a tumour ends, and healthy tissue begins 
is unclear. When it comes to lung cancer, surgeons can be as extreme as to remove entire lungs. 
The primary treatment for early stage (stage I and stage II) NSCLC is surgery7 and offers the 
best route for survival. The 5-year survival rate after surgical resection is 60-80 % for stage I 
and 30-50 % for stage II NSCLC patients. Platinum based adjuvant chemotherapy is normally 
recommended post-surgery and has been shown in clinical trials to improve patient survival 
over 5 years.8 
The primary treatment for stage III and IV NSCLC is a combined use of surgery (if possible), 
chemotherapy and radiotherapy. Recently, antibody-based therapies have come onto the 




(PD-L1) cell surface receptor; an adaptive immune system checkpoint. The treatment was 
approved in 2016 for patients with metastatic NSCLC, however the treatment is only approved 
for stage IV of the disease. In trials is was shown to improve patient survival by 4 months with 
the Atezolizumab vs the control study that did not include Atezolizumab.9 
Based on the statistics presented in the literature, diagnosis of lung cancer at the earlier stages 
would have a significant effect on overall patient survival, with early diagnosis more effective 
than improved treatment options. Whilst new treatment options will always be needed, surgery 
will always be the most effective treatment strategy. Furthermore, the long approval times 
required for new therapies means that improved diagnosis will be far more cost-effective 
approach in helping patients with lung cancer. In conclusion, accurate, cost effective 
diagnostic methods for identifying lung cancer at early stages are required in clinical settings. 




1.2 Medical imaging 
1.2.1 Established techniques 
Diagnosis is a key step in identifying the location and type of cancer. A correct diagnosis will 
mean that treatments can be more specific and effective. Moreover, the identification of 
tumour margins is crucial for successful surgical outcomes and cancer follow-up treatments. 
The process of diagnosis usually begins with non-invasive medical imaging, followed by a 
potentially invasive biopsy that then identities the cancer more accurately via biomarkers and 
histological methods. 
In the field of medical diagnosis one of the most powerful tools is the use of light and many 
different wavelengths from the electromagnetic spectrum have been utilised. One of the most 
important discoveries in this field was X-rays. Originally discovered by Röntgen in 1895, they 
revolutionised our ability to understand bone injuries. These days X-rays are simple to 
generate and are used pervasively due to the cost-effective information that they provide 
clinicians.10 As technology evolved computed tomography (CT) X-rays were developed. This 
technique involves taking multiple X-rays from different positions around the same point of 
the body, then processing the 2D images to generate a 3D image. 3D images provide a greater 
detail and providing key information that affects treatment options. Naturally, a CT scan takes 
longer than a single X-ray though a key limitation is that they have poor soft tissue resolution,11 
though to circumvent this iodinated contrast agents can be used to improve the resolution of 
the images generated (Figure 1.3).12 
 
Figure 1.3 An example of an ionic iodinated CT contrast agent called diatrizoate (trade name 
Hypaque). 
Another technology that has come to the forefront of medical diagnosis is magnetic resonance 
imaging (MRI). MRI works by reversing the spin of the nuclei in hydrogen atoms in water 
using an electromagnetic field. When the magnetic field is switched off the nuclei return to 
their resting state, and in doing so cause a release of electromagnetic radiation which can be 




the human body13 and makes MRI a powerful tool for imaging certain areas of the body such 
as the brain and other soft tissue areas. There are two issues with using MRI on the lungs, the 
first, is that lungs consist of mostly air and the lack of water gives poor contrast. The second, 
is that the movement caused by breathing makes calibration of the machine difficult. A CT 
scan is therefore likely to be the first imaging technique that would be used to try and pinpoint 
the location of a tumour. However, a scan that utilises nuclear imaging might be used to get a 
better idea of the tumour location and staging. 
This includes positron emission tomography (PET), another important technique in the field 
of cancer diagnosis. PET works by using radioactive isotopes that undergo positron emission. 
These positrons collide with electrons in the surrounding tissue undergoing self-destruction 
generating two gamma photons that are emitted at a 180 ° angle to each other and 18-Fluorine 
is one such radioisotope capable of this emission. In cancer imaging, the molecule 
fluorodeoxyglucose ([18F]FDG) (Figure 1.4) is frequently used to detect tumours.14 Its use is 
based on the assumption that, because cancer cells grow faster they consume larger amounts 
of glucose. Thus, their uptake of FDG will be higher than normal cells.15 Upon uptake, 
[18F]FDG is phosphorylated by hexokinase which prevents the molecule leaving the cell, 
effectively trapping the molecule inside the tumour.15  
 
Figure 1.4 Structure of Fluorodeoxyglucose ([18F]FDG). 
Current medical imaging techniques all have limitations, for example CT scans and X-rays 
lack sufficient specificity for truly accurate diagnosis of cancer. MRI and PET have much 
higher specificity and can diagnose cancer. Indeed, PET and MRI imaging can reveal some of 
the molecular specificities of a patient; for example, the presence/activity of receptors on the 
surface of cells. However, PET requires the use of radioactive traces which can be expensive 
and difficult to synthesise, while MRI scans often take a significant amount of time and is also 
expensive to carry out. Crucially, none of these techniques can be used in real time (during 
surgery) with current equipment. As discussed before, the best survival prognosis for patients 
comes when they undergo surgery to remove all the cancerous tissue and ideally the imaging 
techniques should help guide this. Consequently, many researchers are looking to develop new 




common, however fluorescence-based probes need to avoid the intrinsic autofluorescence of 
physiologically relevant molecules such as haemoglobin. As a result, an in vivo imaging 
window has been conceptualised (Figure 1.5) and used to describe the use of light in the visible 
and near infra-red wavelengths that can be used to image biological tissues in vivo. 
 
Figure 1.5 The in vivo imaging window. A graph plotting wavelength versus the extinction coefficients 
of several physiological relevant molecules. Adapted from reference 20. 
1.2.2 Fluorescence and quenching 
Fluorescence is a phenomenon that allows the emission of light (as photons) from a compound 
after the absorption of a photon. The energy of the source photon excites one of the molecular 
ground state electrons inducing it to an excited energy level S1 (Figure 1.6). According to 
Franck-Cordon rules the electron can occupy any number of vibrational energy states. The 
electron will vibrationally relax to the closest semi-stable energy level, before moving down 
to the lowest excited state S1 (Figure 1.6) by a process called internal conversion. Kasha’s rule 
states that fluorescence will only occur from the lowest excited level (S1). The electron will 
then transition to the ground state from the excited state, as it does it can emit the energy either 
as a photon (fluorescence), or through non-radiative relaxation that causes no emission. 
The electron can also move to an excited triplet state T1, in a process known as intersystem 
crossing (ISC, Figure 1.6). Intersystem crossing is highly unlikely as it involves a forbidden 




state can relax from T1, to S0 releasing the energy as a photon (phosphorescence), or a non-
radiative relaxation. 
The photon emitted is always lower in energy than the photon absorbed meaning emission 
wavelengths are always longer than the excitation wavelengths. The difference between the 
excitation and emission maxima is known as the Stokes shift, indicative of the journey 
travelled by the photon, with a small Stokes shift suggestive of energy loss simply through 
changes in vibrational energy states, whereas, a large Stokes shift implies significant energy 
loss due to excited state transitions. The efficiency of fluorescence can be determined through 
its so-called quantum yield; the percentage of photons emitted divided by the total number of 
photons absorbed. The quantum yield, in addition to the extinction coefficient of the 
fluorophore, can be used to define the ‘brightness’ of the fluorophore. 
 
Figure 1.6 Jablonski diagram illustrating the process of fluorescence and phosphorescence. Solid 
arrows indicate absorption and emission routes while dashed arrows indicate methods of relaxation. 
There is also a way to prevent fluorescence emission via a process known as quenching. One 
mechanism is when fluorescence is quenched through a process known as Förster resonance 
energy transfer (FRET), involving two chromophores a donor and acceptor (Figure 1.7). The 
donor chromophore will absorb a photon from an external source and become excited. In 
fluorescence this energy would be emitted, however the presence of an adjacent acceptor 
chromophore means that the energy can be transferred to the acceptor chromophore. This 
process is distance dependent and only works effectively when the two molecules are in close 
proximity to one another (typically less than 10 nm). Simply put, a quencher is a molecule can 





Figure 1.7 Förster resonance energy transfer. (A) The spectral overlap required between the 
donor’s emission and the acceptors excitation spectra. If there is no overlap the acceptor cannot 
absorb the emitted donor photon as it has the wrong energy levels (B) Distance dependence of 
FRET, when the donor and acceptor molecules are far away from each other the efficiency of 
FRET is decreased, whereas molecules close to each other have a high efficiency. Fluorescein and 
tetramethylrhodamine (TRITC) are a common FRET pairing. 
1.2.3 Fluorescence guided surgery 
Surgical resection of tumours is one of the best ways to improve patient prognosis, however 
an issue is tumour margin identification which even today is subjective. There have been recent 
developments of fluorescent probes with molecular targeting moieties which can be used to 
image margins in vivo and in real time causing much more contrasted tissue boundaries. 
Additionally, accurate identification of tumorous margins should also result in the preservation 
of healthy tissue, helping patient outcomes by not damaging the body unnecessarily.  
In 2011 researchers used a folate-fluorescein isothiocyanate conjugate (Figure 1.8) to image 
ovarian cancer during a surgical procedure.16 Ovarian cancers are known to overexpress folate 
receptors, allowing the folate-FITC conjugate to selectively label these cancerous cells over 
healthy cells. Patients were given the compound 2-8 hours before surgery to allow time for 




surrounding tissue. The patients underwent surgery, during which fluorescent and brightfield 
cameras were used to image the ovaries. Interestingly the researchers found that using the 
fluorescent camera allowed them to find extra subsidiary cancers which could not be identified 
by the brightfield cameras or the surgeons’ eye.  
 
Figure 1.8 The folate FITC conjugate from reference 16. This conjugate is an example of a 
fluorescent molecule linked to a targeting moiety.  
To improve this probe, the FITC fluorophore was changed to a cyanine dye which fluoresces 
(emits) at longer wavelengths (795 nm vs 520 nm). Using near infrared wavelengths of light 
allows for improved tissue penetration but also better contrast against the background 
fluorescence that tissue can have.17 The folate-cyanine dye conjugate was first used to image 
lung cancer adenocarcinomas in mice17 and then subsequently used in a phase I clinical trial 
on 20 patients to establish if it would improve tumour margin identification. Patients received 
an intravenous injection of the compound 3-6 hours before surgery.18 The result of this trial 
suggested that tumour margin identification was improved and also that extra tumours were 





Figure 1.9 Left, brightfield images of ovarian cancer. Right, Fluorescence image of the same region, 
(images are taken from reference 16). The green tissue indicates binding by the Folate receptor 
highlighting cancerous cells. *Note: no scale bar published. The green cancer cell clusters are likely 
between 1-15 mm. 
Another probe of note is GE-13719 which was used to detect colorectal cancer polyps. The 
probe GE-137 consisted of a 26 amino acid bicyclic peptide which was able to bind to the cell 
surface receptor C-Met and was linked to a Cy5 cyanine dye known as Cy5** which contains 
multiple sulfonate groups. In a pilot study the probe was intravenously injected into patients 3 
h prior to imaging and during the colonoscopy imaging process, a dual fluorescence and 
brightfield imaging system was used. In the first imaging pass to identify cancerous polyps, 
101 were detected across the 15 patients, and in the second pass an additional 22 polyps were 
detected (across the 15 patients), however 17 of these 22 polyps were only detectable using 
fluorescence imaging i.e. they were invisible to detection under brightfield illumination. This 
is yet another example of fluorescence being used to image tumours during surgery to improve 





Figure 1.10 Six images of colorectal polyps taken from reference 19. Brightfield and corresponding 
fluorescent images are shown. Arrows indicate precise location of polyps. 
The probes described above are known as “always on” since their fluorescence can always be 
detected which can lead to high background fluorescence levels and much work has gone into 
the development of “switch-on” probes. These are molecules, which, upon interaction with 
some environmental activator, will increase their fluorescence output. These probes can then 
take advantage of the unique conditions that are created by disease states, these include: pH, 
enzymes and metabolites.20,21 
It is hypothesised that proteases such as matrix metallo proteins (MMPs) could be exploited 
to image tumours 22 as they have been implicated in the growth of tumours by remodelling the 
extracellular matrix. This allows the cancer cells to spread into their surrounding tissue more 
easily.23 The selectivity of MMPs has been manipulated using activity-based (“switch-on”) 
probes, by utilising a fluorophore-quencher (FRET) pairing held in proximity by a peptide 
sequence. These probes could then be “activated” or “switched on” by cleavage of the peptide 
sequence leading to an increase in florescence.  
In work by Crisp, an activatable cell penetrating peptide (ACPP) probe was used to image 
tumours in vivo.24 The ACPP would be cleaved by MMP-2, activating it and allowing the cell 
penetrating peptide-Cy5 probe to bind to the plasma membrane and be up-taken into cells, 
allowing them to be imaged (Figure 1.11). This probe extended to include an integrin binding 
motif (cyclic RGD peptide) which was found to greatly enhance the up-take of the probe by 
10-fold into U87MG cells (in vitro). In MDA-MB-231 tumours the probe, gave enhanced 






Figure 1.11 (A) The MMP-2 is linked to a membrane bound integrin. The APCC binds to this protein 
complex through the cyclic RGD. MMP-2 then cleaves the probe into two fragments. The CPP-Cy5 
fragment then binds to the Cell membrane and is uptaken into the cell. (B) In vivo breast tumour 
imaging with dual-targeted ACPPs. Dual-targeted cyclic-RGD-PLGC(Me)AG-ACPP, single-targeted 
(cyclic-RAD-PLGC(Me)AG-ACPP and cyclic-RGD-PEG6-ACPP), and double-negative cyclic-
RAD-PEG6-ACPP peptides were injected into mice harbouring bilateral orthotopic MDA-MB-231 
breast cancer tumours. Six hours after a 10 nmol dose, mice were anesthetized and imaged for Cy5 
fluorescence. Tumours are indicated with white arrows. Adapted from reference 24. 
In conclusion, fluorescence based medical imaging would provide a novel, cost-effective, fast 
method for imaging tumour margins and potentially diagnosing the cancer itself. It also 
provides an opportunity to supplement existing techniques. Fluorescent probes are 




vivo imaging qualities including brightness, stability, solubility. They can be conjugated to 
specific biomarkers to reveal greater details about the heterogenetic status of the cancer. This 
could lead to better chemotherapy treatments as cancer well be characterised to a higher 
specifically and therefore chemotherapy drugs with the lowest risk of encountering drug 
resistance mechanisms can be used. Ultimately surgeons want to move from heavy reliance 
on pre-operation CT scan images (Figure 1.2) to real-time imaging methods (Figure 1.9 and 
1.10) that can accurately image tumour margins which would improving patient prognosis. 
1.3 Cancer treatment 
After Diagnosis, the patient has to undergo various treatment options and nearly all patients will 
have a course of chemotherpy.25 Such agents are simply toxic compounds that kills cells with 
their mechanisms of action often relating to inhibiting processes related to cell division. 
Chemotherapy compounds can be used to treat cancer because cancer cells are dividing rapidly; 
a hallmark of cancer.26 A fundamental limitation of chemotherpay drugs is that they are not 
targeted to the cancer cells, thus they enact their cytotoxic effects on healthy cells throughout 
the body and this causes the severe side effects that patients experience when undergoing 
chemotherpy treatment. The drug Cisplatin (Figure 1.12) has been used in chemotherapy 
treatment for over 50 years, and causes DNA cross linking to facilitate gross genetic damage 
and thus initiate cell death and is used to treat meany cancers inclding lung cancer.27 It typifies 
the pros and cons of chemotherapy dugs: a highly toxic compounds which will kill most cancer 
cells and increase life span, but at the cost of severe side effects which may reduce quality of 
life and may not work for every type of cancer. 
 
Figure 1.12 Sturcture of cisplatin. 
 
To overcome the side effects of chemotherpay drugs, researchers have developed vairents called 
prodrugs. A produg is a non-toixc form of a drug which upon activation (by environmental or 
chemical mechanisms) becomes toxic28 and by expoliting the unique phisological properties of 
tumours (like lower pH and overexproressed proteases) drugs can be activated at the tumour 
site. Capecitabine is a modified version of the drug 5-fluorouracil which when administered 






Figure 1.13 Capecitabine as an example of a prodrug that requires multiple enzymatic activation steps. 
The enzymatic bioconversion initiates in the liver, where human carboxylesterases 1 and 2 (CES1 and 
CES2) cleave the ester bond of the carbamate. This is followed by spontaneous decarboxylation 
reaction resulting in 5′-deoxy-5-fluorocytidine. Generation of the parent drug continues in the liver, 
and potentially tumours, by cytidine deaminase (CDA), which converts 5′-dFCyd to 5′-deoxyuridine. 
Finally, thymidine phosphorylase (dThdPase) liberates the active drug 5′-fluorouracil in tumours.29 
Adapted from reference 29. 
 
Exciting new therapies that have come onto the market are antibody drug conjugates (ADCs) 
which are antibodies that have cytotoxic drugs attached to them. The concept being that the 
antibody can target the drug to the cancer site only, thus reducing off target toxicity. In doing 
so, drugs which have high toxicity (previously discarded from drug pipelines) can now be used 
beauase of this targeted approch since the toxicty is restricted to the cancer site. Indeed due to 
low amounts of antibody binding to a cell the drug must be “super toxic”, meaning that they’ve 
overcome a key limitation of chemotherapy. The concept has been around for several decades 
but only now are effective antibody drug conjugates beginning to reach the market. This topic 
is discussed in greater leangth at the beginning of  Chapter 3. 
1.4 Conclusion 
There is an unmet need in being able to rapidly diagnose lung cancer and to highlight tumour 
margins.  By increasing the number of patients diagnosed at stage I and II, more patients would 
qualify for surgery, tumours would be more responsive to adjuvant chemotherapy treatments, 
and this would lead to an overall increase in survival rates without the need for expensive 
immunotherapy drugs which only minimally extend a patients’ life. Developing better 
diagnostics methods also offers a more cost-effective than developing new treatments, while 




Currently diagnostic methods for lung cancer include CT, PET and biopsies; all of which have 
limitations from a health economics viewpoint. CT and PET are techniques which can image 
large areas (and potentially all) of the body which enables clinicians to identify where in the 
body there might be cancers; this includes potential metastasises. However, CT and PET are 
unable to provide information about the genetic profile of the tumour. A biopsy on the other 
hand, can reveal huge amounts of genetic information about the tumour as the cells extracted 
during the process can be profiled. The disadvantage of a biopsy, beside the invasiveness of the 
procedure for the patient, is that it only profiles the cells extracted. If the tumour is very large 
the biopsy may not capture the full heterogeneity of the tumour mass, moreover to profile any 
metastasises a biopsy for each one must be taken. Thus, fluorescence-based techniques may 
circumvent these issues.  
By developing fluorescence-based imaging techniques, specific to the biomolecular signatures 
of tumours would allow real time analysis and detection of tumours. However, what would also 
be beneficial would be to have control over when fluorescent signals are activated and to be able 
to brightly label tumour margins. As a result, the overall aim of this thesis is to develop lung 
cancer targeting probes which could “switch-on” fluorescent signals or activate prodrugs, 





1.5 Thesis aims 
Examining the literature discussed above it is clear that there is a need for new lung cancer 
imaging methods and that the technique of fluorescence might fill this niche, moreover the 
fluorescence signal ideally should be activatable. In the late 1990s/early 2000s a concept called 
antibody directed enzyme prodrug therapy (ADEPT) was in clinical trials though ultimately 
failed and is discussed in further detail later in chapter 3. The following work in this thesis aims 
to develop a technology analogous to ADEPT, namely ADEPT but with a palladium catalyst 
instead of an enzyme (Figure 1.14). Antibodies with transition metals attached have been used 
in a variety of contexts including for the enhancement of cytotoxicity30 and for PET imaging.31 
However, none of the metals attached to the antibodies were used for the purpose of being a 
catalyst. Thus, this work represents the first example a metal being attached to an antibody for 
the purposes of catalysis.  
 
Figure 1.14 Top: Schematic of antibody directed enzyme prodrug therapy (ADEPT). Bottom: 
Schematic of the aims of thesis, a antibody with a palladium catalyst attached. The palladium then 







Therefore, the goals of this thesis were to: 
1. Develop a biocompatible palladium catalyst which can be used to activate fluorescent 
probes in cancerous cells. 
2. Attach the palladium catalyst to a biological targeting molecule such as an antibody. 
3. Test the ability of this targeted catalyst to generate fluorescent signals in translational 
models. 
The long-term aim of this research would be use an antibody-targeted palladium catalyst, that 
could be used to diagnose, locate and treat lung cancer in vivo. Indeed, using these probes to 
image tumour margins would be a powerful tool, especially when combined with prodrug 
activation as tumour reductions could be visualised more easily. Whilst this thesis focused on 
diagnosis, the catalyst could also be used to locate tumour margins during resections and activate 
prodrugs. Prodrug activation at the cancer site would be a route to circumvent the detrimental 
side-effects of chemotherapy treatments analogous to antibody directed enzyme prodrug therapy 
(see Chapter 3). Finally, an antibody-metal conjugate could potentially have other applications 
in biotechnology, for example metal replacement with therapeutic metals (e.g. alpha particle 
emitters) new assays analogous to enzyme linked immunosorbent assays could be developed 





Chapter 2 Solid-phase synthesis of 
biocompatible N-heterocyclic carbene–Pd 
catalysts using a sub-monomer approach 
The following work was carried out with Durgadas Cherukaraveedu. 
Some of the following results are published in: D. Cherukaraveedu, P. T. Cowling, G. P. Birch, 
M. Bradley and A. Lilienkampf, Org Biomol Chem, 2019, 17, 5533-5537. 
 
2.1 Introduction 
2.1.1 Bioorthogonal chemistry 
The development of bioorthogonal chemistries over the last 20 years has led to a dramatic 
expansion of creative ways to study cellular processes. Bioorthogonal reactions have enabled 
the selective visualisation and manipulation of biological processes in living systems and have 
been widely used in a number of applications.32–34 This includes the use of non-native chemical 
reactions to label biological targets or “switch-on” non-toxic/non-fluorescent compounds into 
their active derivatives.  
Necessary features of these reactions include; the scope to be carried out in complex 
environments (often cellular) without side reactions and fast reaction kinetics. The term 
bioorthogonal chemistry was first coined by Bertozzi in 2003, during work where the 
Staudinger ligation was used to selectively modify cell surface membranes loaded with 
synthetic azidosugars.35 Since then, the field has continued to grow and this has led to a number 
of concepts such as the Cu(I) catalysed azide alkyne cycloadditions (CuAAC),36 strain 
promoted azide alkyne cycloaddition (SPAAC)37,38 and the inverse electron demand Diels-





Figure 2.1 Examples of bioorthogonal reactions (A) The Staudinger ligation (B) The SPACC rection 
(C) The Inverse Diels-Alder tetrazine ligation. The orange circle represents the target molecule e.g. a 
protein. The green star represents an imaging agent e.g. a fluorophore or radioactive isotope. 
 
Within the field of bioorthogonal chemistry, transition metal mediated bioorthogonal reactions 
are also of interest. This is because like the reactions in Figure 2.1 they can enable an array of 
non-natural chemical transformations that can be used to modulate living systems,40–44 but can 
do so with much greater scope and feasibility. 
 
2.1.2 Transition metals in bioorthogonal chemistry 
Six transition metals have been used in the exploitation of bioorthogonal reactions. One of the 
first examples was demonstrated by Meggers who used a ruthenium catalyst to de-cage bis-





Figure 2.2 (A) Activation of bis-allyloxycarbonyl rhodamine 110 to rhodamine 110 (λEx/Em 
498/521 nm). (B) Hela cells were incubated with bis-allyloxycarbonyl rhodamine 110 (100 
µM) for 30 min. The cells were washed, and the Ru catalyst was added (20 µM) with 
thiophenol (500 µM). The left image was taken immediately after addition of the catalyst, the 
right was taken after a further 15 min. Adapted from reference 43. 
 
Since then, a number of other ruthenium complexes (Figure 2.3) have been developed, 
including a series of more biocompatible ruthenium complexes for fluorophore and pro-drug 
activation.46 Ruthenium has also been used in creative ways for different purposes, for 
example, it has been used as a catalyst to selectively activate DNA binding molecules. The 
molecules when bound to DNA then fluoresce, allowing imaging of the cells using methods 
such as flow cytometry.47 Furthermore, ruthenium has been used to active luciferase substrates 
(which subsequently react with the luciferase) thus creating a real-time reporting system of 
catalytic activity.48 One recent piece of work with a ruthenium catalyst showed that when 
conjugated to a mitochondrial targeting moiety (Figure 2.3), subcellular localisation of the 





Figure 2.3 Left. Ruthenium complexes developed by Meggers that were catalytically active inside cell. 
Right.46 Mitochondria targeting ruthenium catalyst developed by Mascarenas for subcellular 
localization of catalysis.49 
 
Copper is another frequently used metal and is attractive for its catalytic role in the CuAAC 
reaction.50,51 Clavadetscher functionalised TentaGel resin with amino groups, to entrap Cu 
onto the surface. (Figure 2.4). The Cu-nanoparticles then catalysed the synthesis of a 
mitochondria targeted coumarin using a coumarin azide and an alkyne linked lipophilic cation 
via the CuAAC. This reaction was carried out in vivo, the Cu-nanoparticles implanted into the 
yolk sac of zebrafish 24 h after fertilisation. After 3 days, with no display of toxicity, the 
coumarin-N3 (5 µM) and an alkyne linked lipophilic cation (5 µM) were injected, and 





Figure 2.4 (A) Synthesis of Cu nanoparticles on Tentagel resin. (B) Synthesis of a fluorescent 
mitochondrial targeting compound via the CuAAC using the Cu Nanoparticles. (C) Demonstration of 
the reaction in the yolk sac of zebrafish, the heat map indicates levels of fluorescence indicated by the 
white arrow (scale bar 250 µm). Adapted from reference 49. 
 
Gold catalysts in living systems have also gained popularity.52–54 A prominent example by 
Tanaka and co-workers used a fluorescently labelled Au(III) complex (see Figure 2.5) that was 
coordinated to N-glycoalbumin through hydrophobic interactions. The N-glycoalbumin-
Au(III) complex was administered intravenously into mice with accumulation in the liver and 
intestine due to the glycans present on the complex. After 30 min an O-propargylated cyanine 




2 hours, with the Au(III) complex catalysing the activation of a fluorescent imaging agent. 
This work demonstrates an important step for gold metal catalysis in vivo.54 
 
Figure 2.5 Overview of the work by Tanaka. (A) Two glycoalbumins were developed one to target 
the liver the other the intestine. (B) A coumarin-Au(III) complex was attached to these glycoalbumins 
via a hydrophobic interaction between the coumarin and albumin. (C) The glycoalbumin Au(III) 
complexes were injected intravenously into mice (3.4 nmol) and after 30 min a second injection with 
a Protected Cy7.5 imaging agent (5 nmol) was administered. (D) Structure of protected Cy7.5. Image 
adapted from reference 52. 
 
Whilst ruthenium, copper and gold are interesting examples of metals used for catalytic 
reactions inside living systems, other metals have also been tried. Iron and iridium are two 
such examples, though their use in the biological settings has been limited to just one example 
each.55,56 Of all the transition metals, palladium is by far the most utilised in a biological 
setting57,58 and was the first that was specifically delivered into cells and used for novel carbon-




2.1.3 Palladium chemistry in biological settings 
Palladium has gained popularity in bioorthogonal chemistry due its ability to perform catalytic 
cross-coupling reactions, enabling the generation of carbon–carbon and carbon–heteroatom 
bonds under mild, biological conditions.59–61 Palladium catalysts have been used to initiate a 
range of intracellular reactions including dealkylation,62,63 decaging of propargyloxycarbonyl 
and allyloxycarbonyl groups,60,61,64–68  as well as Suzuki–Miyaura cross-couplings (Figure 
2.6).69,70  
 
Figure 2.6 Summary of the first intracellular palladium reactions by Yusop. A nanoparticle with 
Pd(0) entrapped on the surface. These Pd-nanoparticle were able to catalyse: (A) A Suzuki-Miyaura 
cross coupling reaction that generated a fluorescent dye with a mitochondrial localising moiety. (B) 
The decaging of a caged fluorophore bis-allyloxycarbonyl rhodamine 110 to rhodamine 110. 
Adapted from reference 55. 
 
Other work that included palladium mediated reactions in cells, have been the selective 
activation of enzymes through deprotection of modified amino acids within proteins60 to the 
synthesis of anticancer agents in cellulo from two benign precursors;61 as well as activation of 
prodrugs.62,63,68 To date, the majority of examples have used Pd(0) nanoparticles entrapped 
within a polymeric nanoparticle support61–63,66–69,71 (Figure 2.6), or simple palladium salts such 
as Pd(OAc)260,70 although these are toxic. 
There is a desire to move toward the use of small molecule homogenous palladium catalysts. 




stabilising ligands e.g. phosphine or N—heterocyclic carbene (NHC) ligands but few have 
been used in a biological setting.  
Work to date has included the use of NHC-Pd catalysts in a biological setting with a NHC-Pd 
salt used to carry out a Suzuki–Miyaura cross coupling on the cell surface to label the cells 
with biotin.70 Another example was the development of a water soluble NHC-Pd catalyst65 that 
used a cell penetrating peptide72 to increase uptake into cells and then catalytically activate a 
caged fluorophore (Figure 2.7). The most recent work was carried out by Mascarenas, who 
developed a series of palladium catalysts with simple phosphorous based ligands that were 
attached to mitochondrial targeting moieties (Figure 2.7). Though these compounds were 
relatively insoluble in aqueous media, they were successfully identified within mitochondria 
and used to switch on fluorophores in the mitochondria preferentially over the cytoplasm.64 
 
Figure 2.7 (A) The catalyst made by Indrigo with a poly-cationic sequence to enhance cellular 







2.1.4 Chapter aims 
Based on the previous work described, there is currently a niche for a homogenous Pd-catalyst 
that can specifically target cancer cells directly. There was a desire to synthesise a palladium 
catalyst designed with the express intent of having a bioconjugation handle so that it could be 
coupled onto a targeting molecule. This is something that has not previously been explored for 
any metal. The catalysts synthesised need be catalytically active inside cells given the desired 
application for use with antibodies in vivo i.e. water soluble and biocompatible.  
The Pd-catalyst would follow the structure previous devised by Meldal73 and further developed 
by Indrigo (Figure 2.8).65 The final coordinating ligand is currently undefined in the literature 
and is presented here as Y, but would be a highly labile ligand which could be easily exchanged 
to convey catalytic activity (this is discuss in more detail later in this chapter). The synthesis 
of these ligands would incorporate solid phase peptide synthesis methodologies and the use of 
a chlorotrityl linker to generate a carboxylic acid moiety at the end of the molecule. This 
carboxylic acid could subsequently be “activated” into an NHS-ester for conjugation to 
biomolecules via amide bond formation.  
After successfully devising a methodology for synthesising this catalyst, it could be used to 
explore creating catalysts with different linkers and thus build a library to validate the 
robustness of the synthetic strategy. These catalysts will need to be tested for their ability to 
catalyse a de-propargylation reaction, key for the “switch on” mechanisms desired for in vivo 
studies. be, however the catalyst can be tested on a translatable model such a 3D spheroids – 
model yet to be used in bioorthogonal chemistries. 
 
Figure 2.8 Structure of the desired NHC-Pd catalytic centre with an additional moiety for 








2.2.1 Synthetic strategy for synthesis of N-Heterocyclic 
Carbene-Pd catalysts 
A general structure for the palladium catalysts needed is shown in Figure 2.8., however the 
first palladium catalyst was chosen to be made is shown in Figure 2.9. This catalyst contains 
an amino hexanoic acid linker acting as a spacer between the palladium centre and a carboxylic 
acid group. The purpose of the carboxylic acid is to be activated into an N-hydroxysuccinamide 
ester. This basic catalyst structure contains all the desired properties for eventual 
bioconjugation to proteins. 
 
Figure 2.9 The initial palladium catalyst to be made that incorporated the features desired. The 
catalytic centre and a carboxylic acid for future bioconjugation strategies. 
 
 The moiety of conjugation should be able to catalyse a range of reaction but the most desired 
is the removal of propargyl groups from molecules such as fluorophores. The general 
mechanism for de-propargylation is shown in figure 2.9. The exact nature of the catalytic cycle 
is still debated and likely follows a variety of route. Recently, Coelho suggested that the 
catalytic cycle might have a bi-phasic kinetic profile.74 The general mechanisms that they 
suggest for palladium catalysts of different oxidation states is shown in figure 2.10. Generally, 
The palladium catalyst will interact with the π-bonds of the alkyne and either use it as a ligand 
(Pd(II/IV) catalysts) or form a direct bond (Pd(0) catalysts). During this step the rest of the 
propargyl group might be released in the Pd(0) mechanism. Then the alkyne can be subjugated 
to a nucleophilic attack and this will likely be water in a biological system due to its abundance. 
The molecule then undergoes a tautomerization followed by a second nucleophilic attack and 
then release of the products and restoration of the original catalyst. These mechanisms are still 
unconfirmed and in all likelihood, there could be a variety of other things happening for 





Figure 2.10 De-propargylation reaction catalysed by palladium. Top: Proposed mechanism of 
deprotection using a palladium II or IV catalyst. Bottom: Proposed mechanism of deprotection 
using a palladium 0 catalyst. Adapted from reference 74 
 
To make the homogeneous catalyst shown in Figure 2.9, the synthesis began with a two-step 
synthesis of a pyridine-based imidazolium ligand (3a). This ligand is able to coordinate 
palladium through: the nitrogen lone pair on the pyridine ring, a carbene (that was) generated 
from the imidazolium, and the carbonyl from the carboxylic acid group. This ligand had been 
modified from an existing structure and was devised by Meldal.73 The procedure followed the 






Scheme 2.1 (i) NH3, glyoxal, formaldehyde, iPrOH, 80 °C, 18 h; (ii) 2-(bromomethyl)pyridine 
hydrogen bromide, DMF, 150 °C, 25 min, µW; (iii) TFA, 1 h. 
 
The first reaction was a Debus-Radziszewski imidazole synthesis with the driving force behind 
the reaction the generation of an aromatic system through the loss of water (Scheme 2.2). 
 
Scheme 2.2 Debus-Radziszewski imidazole synthesis proposed for the reaction in Scheme 2.1. First 
the primary amine from the amino acid forms and imine with glyoxal. The remaining carbonyl from 
the glyoxal is then attacked by ammonia to form a second imine following the loss of water. 
Cyclisation occurs with the loss of water again the driving force. 
 
While the yield of this reaction was poor (30 %) by comparison to the reported literature (60 
%) (Table 2.1), the starting reagents were commercially available and carried out on a 
multigram scale. The low yield was attributed to the multiple side products formed, including 
imidazole, formed by the addition of two ammonia groups (Table 2.1). Minor alterations to 











Following isolation of the imidazole product, it was N-alkylated through an SN2 substitution 
using 2-(bromomethyl)pyridine hydrogen bromide. The reaction was carried out under 
microwave irradiation before removing the tert-butyl group with TFA (Scheme 2.1). Whilst 
the conversion of 2 to generate 3a was typically 30 % the isolated yield was often only 5 % 
(isolation was carried out by preparative reverse phase high pressure liquid chromatography 
(RP-HPLC)). Multiple attempts to purify the compound using different methods (such as de-
activated silica, alumina) did not result in higher yields. Using RP-HPLC gave the highest 
purity of the compound and was thus favoured, but gave low yields, yielding only 20 mg of 
3a from 350 mg of 2. 
 
Scheme 2.3 Coupling of 3a on to an amino acid attached to a solid phase support via a linker; (i) 
TBTU, NEM, DMF, 20 min, 60 °C, µw. 
 
3a was then coupled onto an amino acid via solid phase synthesis (see Scheme 2.3) with 2-
(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) used as a 
coupling agent with the base N-ethyl morpholine (NEM) in DMF. The solution was heated to 
60 °C for 20 minutes with the coupling confirmed by a negative Kaiser test (absence of 
primary amine groups). With the successful coupling, palladium could then be loaded to 
generate the final catalyst 3c (Scheme 2.4). 
 
Table 2.1 Reaction conditions explained to give compound 2. 
Conditions and (reaction scale) Yield (%) 
Literature procedure (0.5 g), 6 h 40 
Literature procedure, reaction time 
18 h (0.5 g) 
33 






Scheme 2.4. Palladium loading into the ligand; (i) Ar, BEMP, 45 mins r.t.; (ii) DMF, Pd(COD)Cl2 
O/N, r.t. 
 
Due to the poor yield and time taken to generate 3a, a new methodology was devised based 
on the retrosynthesis proposed in Figure 2.11. Given the availability of starting reagents it 
was hypothesised that the organic ligand in compound 3a could be synthesised using a sub-
monomer type approach first devised by Zuckerman for the synthesis of N-alkylated 
peptoids.75,76  
 
Figure 2.11 Retrosynthesis of the palladium coordinating ligand. (i) N-alkylation with Bromomethyl 
pyridine; (ii) N-alkylation with imidazole; (iii) Amide bond formation. 
 
Using this synthetic route, bromoacetic acid could be coupled onto a primary amine (attached 
to a solid support via a linker) by activating the carboxylic acid with DIC. Next imidazole 
could substitute the bromine group via SN2 substitution. Finally, an N-alkylation using 2-
bromomethyl pyridine could be carried out (Scheme 2.1). This synthetic route was used so 
that all reactions were carried out using solid-phase synthesis methods thus reducing the 
number of purifications step, increasing the efficiency and giving an overall simpler synthetic 
route. 
The palladium catalyst was thus created using the overall synthesis shown in Scheme 2.5. 6-
Aminohexanoic acid was used a model amino acid spacer to test different reaction conditions 






Scheme 2.5 Synthetic pathway for the model NHC-Pd catalyst. (i) Fmoc-Ahx-OH (0.3 M), DIPEA 
(0.6 M), dry DMF, 1 h; (ii) 20 % piperidine in DMF, 2 × 10 min; (iii) Bromoacetic acid in DMF (2 
M), DIC (1 M), µw, 20 min, 60 °C; (vi) Imidazole (2 M), AgNO3 (0.5 M), DMSO, µw, 40 min, 60 
°C; (v) 2(bromomethyl)pyridine hydrogen bromide (1.5 M), AgNO3 (0.5 M), Et3N (1 M),  dry DMF, 
µw 90 min 60 °C; (vi) Ar, BEMP, dry DMF, 45 min, r.t., Pd(COD)Cl2 in DMF,18 h.; (vii) 30 % 
HFIP in DCM. 
 
Using a 2-chlorotrityl linker on a polystyrene resin (mesh 100-200), Fmoc protected 6-
aminohexanoic acid in the presence of DIPEA in anhydrous DMF was attached to the resin 
through an SN1 reaction Scheme 2.6.  
 
Scheme 2.6 Mechanism for first amino acid coupling to the chlorotrityl linker. 
 
Following Fmoc deprotection using 20 % piperidine in DMF, the synthesis of the ligand was 
carried out. Starting with the free primary amine, an amide bond was created by adding 
bromoacetic acid (2 M) with the coupling agent DIC (1 M) to create an anhydride susceptible 






Scheme 2.7 Mechanism of amide bond formation using DIC as a coupling agent that generates the 
symmetrical anhydride. 
 
The reaction to generate compound 6 from 5 was monitored by the Kaiser test. Following the 
successful coupling, the bromine group from compound 6 was then displaced by imidazole to 
generate 7. Several reaction conditions were trialled, and it was found that the presence of 
silver nitrate improved the conversion (Table 2.2 and Figure 2.12) with DMSO as the optimal 
solvent. It is known that silver nitrate reacts with haloalkanes (often forming silver-halogen 
salt precipitates). It was hypothesised that the silver ion interacts with the bromine to polarise 





Scheme 2.8 Generation of 7. (Top) Proposed mechanisms of imidazole substitution using silver ions 
improving the bromines atom’s ability to act as a leaving group. (Bottom) The mechanism without the 
silver ions. 
 
The optimisation of the on-resin alkylation of 6 was carried out under microwave heating (60 
°C, 25W, 40 min). At the end of the reaction, 7 was cleaved off the resin with 30 % HFIP in 
DCM (45 min) and the purity analysed by HPLC and 1H NMR.  
 
Table 2.2 Different reaction conditions used to substitute the bromide by an imidazole 
group. (generating 7 from 6) a Determined by HPLC (ELS detection). b Determined by 1H 
NMR. 
Entry Imidazole (M) Additive Solvent Conversion (%) 
1 1 None DMF 50a 
2 1 Et3N 1 eq. DMF 60b 
3 1.5 Et3N 1 eq. DMSO 75b 
4 1.5 None DMSO 77b 








Figure 2.12 Normalised HPLC chromatograms (detection by an evaporative light scatting detector) 
of the alkylation of 6 after 40 min at 60 °C with μw irradiation. Complete conversion to product 7 
was observed when DMSO was used as solvent with AgNO3 as an additive. Peak at 0.8 min is salts. 
 
It can be seen from Figure 2.9 that full conversion to 7 from 6 was achieved with imidazole (2 
M), AgNO3 (0.5 M) in dry DMSO with 40 min of microwave irradiation (60 °C). The peak 
with retention time of 0.8 min are salts/DMSO traces carried through from the cleavage 
protocol. 
 
Following successful substitution (confirmed by HPLC and 1H NMR) the imidazole on 
compound 7 was then N-alkylated with 2-(bromomethyl)pyridine to form 8 (Scheme 2.9). All 
the reactions listed in Table 2.3 were carried out in DMF under microwave irradiation (60 °C, 
25W, 90 min). After the completion of the reaction, the compound was cleaved off the resin 






Scheme 2.9 Mechanism for N-alkylation of imidazole on the resin. 
 
 
Table 2.3. Different reaction conditions for the N-alkylation using 2(bromomethyl)pyridine 
⸱ hydrogen bromide to give 8. a Determined by HPLC (ELSD and 254 nm). b Determined by 
1H NMR. 
Entry  2-(Bromomethyl) 
pyridine HBr 




1 1.5 M 2 eq. Et3N 30 DMF 50a 
2 1.5 M 2 eq. Et3N 60 DMF 70a 
3 1.5 M 3 eq. Et3N 60 DMF 70a 
4 2 M 3 eq. Et3N 60 DMF 80b 
5 2 M 3 eq. Et3N 90 DMF 96a 
6 2 M 0.5 M Et3N + 0.5 
M AgNO3 
90 DMF 96a 
 
Again, it was found that the presence of silver nitrate helped improve the conversion. In 
addition, the presence of Et3N was critical in neutralising HBr salts from the starting material 
as well as HBr generated during the reaction.  The purity of 8 is shown in two different HPLC 
traces in Figure 2.13, representative of the conversion following the optimised conditions 





Figure 2.13 HPLC chromatograms of crude 8 after cleavage off the resin (crude purity > 95 %). Left: 
detection by ELSD. Right: detection at 254 nm. 
 
Following complete conversion of compound 8, palladium was then loaded into the ligand. 
BEMP (pK ~24) in DMF was added to the resin bound ligand and stirred for 45 minutes. The 
base deprotonates the NHC-imidazole proton to generate the carbene (Scheme 2.10) while the 
other equivalent of BEMP was used to generate the enolate from the α-carbonyl carbon. After, 
the resin was drained and palladium cyclooctadiene chloride in DMF was added, the reaction 
was stirred overnight and coordinated to the ligand complex to give 9 (the resin bound 
catalyst).  
 
Scheme 2.10 Mechanism for the generation of the N-heterocyclic carbene and palladium 
coordination. 
 
With 9 in hand, the resin was repeatedly washed with DMF and DCM, with cleavage from the 
resin achieved using a mixture of TFA, DCM and H2O. The crude product was purified via 
preparative RP-HPLC to give 10 (yield 15 %, purity >95 %). The purity of 10 is shown in 
Figure 2.14 with the HRMS shown in Figure 2.15. To calculate purity, first ELSD channels 
were used to check for no other contaminants such as palladium salts (data not shown), then 
the major peak in the 254 nm channel was integrated and compared to the total integral of all 





Figure 2.14 RP analytical HPLC of compound 10 after purification at 254 nm wavelength. 
 
 
Figure 2.15 Measured (top) and predicted (bottom) HRMS (ESI) spectra for compound 10 [M+Na] 
(calculated 457.0469 for C17H20O3N4Na1106Pd; found 457.0624). 
 
With compound 10 purified and isolated, the next step was to assess the scope of the synthetic 
methodology to determine if it could be replicated for more complex amino acids. Overall, the 
new synthesis route was hugely more efficient than the original approach based on the solution 




2.2.2 Development of a catalyst library  
Having established that the methodology worked, the solid-phase synthesis route was used to 
generate an NHC–Pd catalyst library. The amino hexanoic acid spacer was therefore 
substituted with a range of amino acids with all catalysts synthesised using the chloro-2-
chlorotrityl linker on a polystyrene resin.  
The range included hydrophobic, aromatic, and charged amino acids to compare the potential 
effect on catalytic activity, as well as the robustness of the synthetic method (Figure 2.16). 
ranging from single amino acids e.g. 11 to compound 17. Furthermore, the synthetic 
methodology was also successfully applied to create a tripeptide using an amino methyl 
polystyrene resin functionalised with a Rink-amide linker that generated a terminal amide 
upon cleavage. 18 was cleaved from the Rink-amide linker using mixture of TFA and H2O 
(19:1) with the NHC-Pd centre stable to these more extreme acid conditions. 
 
Figure 2.16 Library of catalysts synthesised using the synthetic methodology. 
 
For characterisation, the ligands of each catalyst were fully characterised before loading with 
palladium using NMR, HPLC (ELS and 254 nm detection), and HRMS with the final catalysts 
(10 – 18) characterised by HPLC and HRMS. Using compound 11 as an example, the “naked 
ligands” and the Pd-loaded ligands displayed different retention times sufficient for separation 







Fascinatingly, it was found when examining the H1 NMR of some of the ligands prior to 
palladium loading in CD3OD, the N-CH-N imidazole proton was missing (expected chemical 
shift approximately 9.17 ppm). After changing solvent to d6-DMSO both the NHC proton and 
the NH proton from the amide bond became visible, showing that these protons were 
exchanging with the acidic deuterium in CD3OD. This is shown for compound 8 in Figure 
2.18. 
 
Figure 2.17 HPLC analysis (detection at 254 nm) of the ligand and catalyst 11. (A) The Ligand 11. 
(B) Catalyst 11. (C) A sample of catalyst 11 spiked with the ligand, showing the difference in 





Figure 2.18 NMR spectra of compound 8 in CH3OD (Blue) and d6-DMSO (red). In d6-DMSO the 
NHC and NH protons are clearly visible at 9.43 and 8.94 ppm respectively. The proton from a formate 
counter ion is also visible as a singlet at 8.54 ppm. In CH3OD the peaks are no longer visible. The 
carboxylic acid proton was also not observed in CH3OD and beyond the scale at 11.8 ppm in d6-
DMSO. 
 
This proton deuterium exchange might suggest that the phosphazene base, BEMP, used in this 
reaction may not be necessary to generate the carbene, though further experiments would be 
required to test this. The reason why this exchange might be easier could be due to the presence 
of the amide bond. The donation of the nitrogen lone pair into the amide bond likely helps 
form a resonance structure of a 6 membered ring containing: the carbonyl oxygen and carbon 
atoms, the α-carbonyl carbon and imidazole nitrogen, N-C-N carbon and the exchangeable 
hydrogen atom in question. Furthermore, the lone pair from the pyridine ring is likely also 
contributing some bonding which might make a proton-deuterium exchange more likely. 
However, these hypothesises are purely speculation. The ligands for each of the catalysts are 
characterised in methods section (Chapter 5). 
Once palladium was loaded, the catalysts were cleaved off the resin using 30 % HFIP in DCM 
and purified. The purity of the catalysts was analysed by analytical HPLC (Figure 2.19). The 
















Table 2.4. Summary table of the yields, purity by HPLC (ELSD and 254 nm) 
and HRMS of the catalysts 10 – 18.   
Compd. Yield (%) Purity (%) Mass Calcd. Mass Observed 
10 11 94 435.0643 435.0640 
11 8 94 379.0017 379.0025 
12 8 90 407.0330 407.0332 
13 9 82 463.0963 463.0956 
14 13 93 421.0486 421.0491 
15 11 94 469.0486 469.0488 
16 7 95 450.0752 450.0750 
17 7 96 768.2136 768.2120 
18 14 96 624.1545 624.1556 
 
These catalysts (10 mM in CH3CN/H2O (3:7)) were found to be stable for two weeks at room 
temperature, and  8 weeks at 4 °C (Figure 2.20). This was another satisfying finding as in the 
clinical setting these catalysts could remain in the body for a significant period of time if 
attached to an antibody. Antibodies are known for their long half-life’s (>2 months) and thus 
anything that might be attached to them in the future must factor in this consideration. 
 
Figure 2.20 Stability of NHC-Pd catalysts 11, 14 and 17 (t is retention time). 
 
A caveat with the purity analysis is that it was only carried out by HPLC methodology. In this 
analysis both evaporative light scattering (ELS) (data not shown) and 254 nm wavelength 
detections were used. The ELS will detect any molecule including impurities such as potential 
palladium salts and other small molecules with no double bond conjugation moieties while the 
254 nm wavelength detection was used to confirm where the desired product was eluting due 
to the presence of conjugated moieties. The methodologies were set up to ensure that all 




impurities. Moreover, eluting near the injection peak of the sample was also avoided as this 
causes issues with the ELS detection. To calculate the purity of signal deemed to be the product 
(suggested by low resolution mass analysis), the peak was integrated (on the 254 nm channel). 
All other peaks observed were also integrated and the comparison between the two was used 
to calculate the purity (table 2.4). Finally, it is known that the non-palladium bound ligands 
have separate retention times thus their presence could be easily detected if present. 
Anecdotally it also seemed that the catalysts with palladium seemed to have more absorbance 
at 282 nm compared to their non-palladium counterparts, though this was not used as any 
confirmation and is merely an observation. An issue with this methodology, there is no 
certainty that a second compound is not co-eluting with the desired product. However, if there 
was a contaminating product, we would likely have observed this in the mass spectrometry 
analysis. Molar extinction coefficients were not calculated for the compounds and this data 
may have been useful, though this would be calculated via known concentrations which would 
be subject to pipetting errors. 
In conclusion a catalyst library was successfully synthesised with 9 different catalysts 
synthesised, purified and isolated. Whilst the yields were low, much of this can be attributed 
to reactivity of the carbene, as any water in the reaction system could revert it back to it 
protonated precursor thus will not generate the palladium containing product. More 
importantly with the new synthetic methodology, these catalysts can be made from scratch 
rapidly, the Pd ligands can be readily purified. With this success, the compounds were 
screened for their catalytic activity. 
2.2.3 Screening of catalytic activity 
Following the successful synthesis of these catalysts, their catalytic activity was evaluated 
against a protected version of the fluorophore 2,7-dichlorofluorescein (DCF). DCF was O-
propargylated to create the protected version of the fluorophore (Pro-DCF) (synthesised by 
Durgadas Cherukaraveedu). Pro-DCF was converted back to the fluorescent derivative DCF 
(λEx/Em = 500/530 nm) upon Pd-catalysed cleavage of the propargyl group (Figure 2.21). The 
absorption maximum of DCF was found to be 500 nm with emission at 530 nm in accordance 





Figure 2.21 (A) Pd catalysed depropargylation reaction of Pro-DCF to give fluorescent DCF (λEx/Em 
500/530 nm). In the presence of palladium the compound Pro-DCF loses its propargyl group resulting 
in conjugation of the aromatic rings being restored and its fluorescence being “switched-on”. (B) 
Absorption (Solid lines) and emission spectra (dashed lines) of Pro-DCF (red) and DCF (blue). All 
spectra were measured at 10 µM in PBS. 
 
The mechanism of deprotection is suggested in figure 2.22 which was based on the mechanism 
suggested in figure 2.10. The first thing to note is that de-propargylation will not happen 
without the presence of the palladium catalyst, this is observed in figure 2.23 control 
experiments. Initially the palladium catalyst has a highly labile ligand “Y” attached to it. To 
this point Y has not been discussed as it is not clear what it is from mass spectrometry data, 
however that is also indicative about its nature of being labile. It is speculated that Y is likely 
to be a solvent ligand, or some ion found in the solvent to which the compound has been 
exposed to during synthesis and purification. The most likely candidates are as follows with 
an explanation as to where they come from: water, from solvent systems and in biological 
media water is the most abundant molecule in any buffered system; acetonitrile (ACN) from 
HPLC purification systems; chloride ion, sodium chloride is often found in biological 
solutions, it may have also arisen form the palladium chloride source used in the synthesis; 
bromide ion, from the reagents used to synthesise the organic ligand (2-bromomethyl 




HPLC purification systems used; TFA ion, TFA was used in the cleavage of the compound 
from the solid phase resin support. Given the commonality and stability of Palladium II 
catalysts the remaining ligand Y is likely to be neutral i.e. water or acetonitrile. In the 
mechanism this ligand is exchanged with the propargyl group which utilises π-bonding. There 
is then a nucleophilic attack from water (although any nucleophile is possible) as this will be 
the most abundant nucleophile in a biological system, followed by an isomerisation. Finally, 
a second nucleophilic attack occurs with the release of the OR group (the fluorophore). The 
oxidised propargyl group is then released regenerating the catalyst. This description of the 
mechanism is purely speculative and is open to discussion. 
 
Figure 2.22 Proposed mechanism for propargylation of the compound Pro-DCF. Mechanism 
includes the palladium catalyst and suggestions of the identity of the unknown ligand Y. 
 
It is also likely that the nature of side chain R1 also plays some part in the efficiency of the 
catalyst underlining the importance of a screening process to understand which side chain give 
the highest activity. Catalyst screening was carried out at 37 °C in PBS (Figure 2.20) to 




mol %) were incubated with Pro-DCF (10 μM) and an increase in fluorescence measured over 
4 h.  
 
Figure 2.23 (A) Screening of catalysts 11–17 (0.8 mol %) for the activation of Pro-DCF (10 µM) in 
PBS (n = 3). The reactions were monitored over 4 h and an increase in fluorescence recorded over time 
and compared to the blank (no catalyst) and 0.8 mol % Pd(OAc)2. (B) The catalytic decaging of Pro-
DCF (50 µM) with catalyst 11 (2 mol %) was monitored by HPLC (detection at 282 nm) over time with 
the reaction carried out in PBS, showing > 92% conversion. 
 
With the exception of 16 and 13, all the catalysts were active in PBS with 11 and 14 (ligands 
containing glycine and valine amino acids respectively) showing comparable activity to 0.8 
mol % Pd(OAc)2 (Figure 2.23). This was a pleasing result given how versatile Pd(OAc)2 is. 
Catalyst 11 (2 mol %) was further evaluated by monitoring the decaging of Pro-DCF by RP-
HPLC, with the experiments performed in PBS, giving 92 % conversion to DCF after 5 h 
(Figure 2.23).  
Next, the catalysts were screened for their activity in plasma to mirror a cellular environment 
rich in proteins. The decaging reactions were notably slower in cell lysate, but 11 and 14 again 
showed the best catalytic efficiency under these conditions and outperformed Pd (OAc)2 
(Figure 2.24). In plasma, 11 (2 mol %) resulted in a 97 % conversion over 5 h (Figure 2.24). 
The overall trend suggested that the smaller spacers such as 11 and 14 were more active whilst 
larger more hydrophobic spacers like 17 were less catalytically efficient.  
It is clear from these result that the amino acid R groups influence activity. One reason for the 
low activity of compound 16 (lysine linker), 10¸12 and 13 could be related to intermolecular 
interactions with the palladium centre. In compound 16 it is highly possible that the ε-amine 
group on the side chain could interact with the Pd centre and become ligand “Y”. The 
proximity of this group and its ability to bind to the metal may explain why its activity is so 
low. Compounds 10, 12 and 13 are carbon chain of 6, 4 and 8 respectively. At the end of these 
carbon chains is a carboxylic acid moiety. It is hypothesised that these carboxylic acid groups 




chain. The reason why 13 presents nearly no activity is due to the chain length being a 
“perfect” length to bend round and interact with minimal steric hinderance. Compounds 10 
and 12 might just be too short for and thus their interactions with the palladium centre are not 
as constant enabling some catalytic activity. The two groups discussed here are very important 
as they are the most common moieties found on the surface of proteins used for water solubility 




Figure 2.24 (A) Pd catalysed depropargylation reaction of Pro-DCF to give fluorescent DCF (λEx/Em 
500/530 nm). (B) Fluorescence based screening of NHC–Pd catalysts 5–12 (0.8 mol %) for 
depropargylation of the probe Pro-DCF (10 μM) in cell lysate (n = 3). (C) The depropargylation of 
Pro-DCF (50 μM) with catalyst 11 (2 mol %) in plasma monitored by HPLC (detection at 282 nm). 
 
The library of compounds created does have limitations and should be expanded to obtain a 
clearer picture of the effect of amino acids of the catalytic activity, with the sub-monomer 





2.2.4 Prodrug activation in cancer cells and in cancer cell 
spheroids 
Currently most of the work on bioorthogonal metal catalysts is in vitro with only a few 
examples of studies in vivo. Given the often-poor translation between 2D cell culture testing 
and clinical studies we sought to move to a more representative model of cancer growth; 
namely 3D cancer spheroids.  
The catalyst 11 was evaluated for its efficiency to activate the caged anticancer drug 5-fluoro-
1-propargyluracil (Pro-5-FU) (synthesised by Durgadas Cherukaraveedu) into its active drug 
form 5-fluorouracil (5-FU) (Scheme 2.11 and Figure 2.25). 5-FU has been in medical use as 
a clinically approved anticancer agent for 40 years.78 In PBS, 11 converted Pro-5-FU into the 
active drug 5-FU within 48 h, as monitored by HPLC (Figure 2.25) which was a highly 
satisfying conversion. In MCF-7 cells, co-treatment with catalyst 11 (10 mol %) and Pro-5-
FU (100 µM) for 5 days resulted in comparable cytotoxicity (MTT assay) to 5-FU (Figure 
2.25). Catalyst 11 showed only mild toxicity (>87 % cell viability) at 10 µM which suggested 
cell cytotoxicity was due to the activation of the drug. 
 
Scheme 2.11 The Pd-catalysed decaging of the prodrug 5-fluoro-1-propargyluracil (Pro-5-





Figure 2.25 (A) MTT cytotoxicity assay for prodrug activation in MCF-7 cells. The prodrug Pro-5-
FU did not induce cytotoxicity at 100 μM and the NHC–Pd catalyst 11 only showed moderate 
toxicity (13 %) at 10 μM, after 5 days incubation (untreated control cells were defined as 100 % 
viable). Co-treatment with catalyst 11 (10 mol %, 10 μM) and Pro-5-FU (100 μM) for 5 days resulted 
in comparable cytotoxicity to 5-FU. Error bars are standard deviation (n=3) (B) Decaging of Pro-5-
FU (100 µM) with catalyst 11 (5 mol %) in PBS (pH 7.4, 37 °C) monitored by HPLC with detection 
at 282 nm. (C) in situ activation of prodrug Pro-5-FU by catalyst 11 in 3D MCF-7 spheroids. The 
spheroids were imaged for live/dead status, Green cells (λEx/Em 495/520 nm) are live whilst the red 
cells (λEx/Em 595/615 nm) are dead. (i) Untreated spheroid (control); (ii) Spheroid treated with (10 
µM) of catalyst 11; (iii) Spheroid treated with 5-FU (100 µM) resulting in cell death; (iv) Spheroid 
treated with prodrug Pro-5-FU (100 µM) showing good viability; (v) Spheroid co-treated with the 
Pro-5-FU (100 µM) and catalyst 11 (10 µM) showing cell death equivalent to that seen with 100 
µM of 5-FU. Scale bar 100 μm. 
 
Next, MCF-7 spheroids were treated with the prodrug Pro-5-FU and catalyst 11 for 5 days, 
stained with a LIVE/DEAD™ Cell Imaging Kit (λEx/Em = 488/570 nm), and analysed by 
fluorescence microscopy. The spheroids treated with both the prodrug and catalyst satisfyingly 
resulted in cell death comparable to cells treated with 5-FU, whereas treatment with only the 
catalyst or the prodrug Pro-5-FU had no effect on the viability of the 3D spheroids (Figure 
2.25). These results appeared to be extremely encouraging for the 3D cancer model. It was 
assumed that the reaction was happening extracellularly, irrespectively these results 





The aim was to develop a biocompatible, water soluble NHC-Pd catalyst. Through the 
development of a highly efficient microwave assisted solid-phase synthesis based on a ‘sub 
monomer’ approach biocompatible NHC-Pd catalysts were generated on scale. The catalysts 
developed had a range of spacers including alkyl chains, hydrophilic and hydrophobic amino 
acids. The catalysts could be made using both a 2-chlorotrityl and Rink linkers to generate 
different C-terminal groups. Overall, the results present provide a solid platform for further 
work to explore a fuller range of amino acids and spacers to be used. By expanding the library, 
the effect of the juxtaposing amino acid to the catalytic centre can be studied to fully 
understand the kinetics and stability of the palladium centre. Finally, building the catalyst onto 
biomolecules with targeting abilities e.g. the cyclic RGD sequence, is an avenue for more 
biological research. For example, perhaps anchoring the catalyst to the cell surface via 
sugars/lipids/peptides and then carrying out bioorthogonal reactions on the cell surface to 
study membrane dynamics could be of interest. 
Nearly all catalysts produced were able to activate a protected fluorophore Pro-DCF in both 
PBS and plasma with 11 and 14 demonstrating comparable activity to palladium acetate. This 
allows questions to be asked about how the different spaces affect the catalytic activity. 
Though no clear trend is observed it would appear that spacers that contain multiple amino 
acids seem to have lower activity compared to spacers that are single amino acids, however to 
deduce fuller conclusions, more catalysts would need to be made for more accurate 
comparisons. 
Catalyst 11, comprising of the NHC–Pd moiety linked to glycine, was the most catalytically 
active in the series. 11 was able to activate Pro-DCF in a biological setting with comparable 
activity to Pd (OAc)2. Moreover 11 could de-cage the protected anticancer drug (Pro-5-FU) 
in a 3D cancer cell culture model resulting in comparable cell death to 5-FU. This successful 
activation inside a more representative cancer model is of most interest given the overall aims 
of this thesis and the context of applying the catalysts in a clinical setting. Whilst in vivo 
models have been used for other metals, 3D in vitro models have not been studied. This is 
particularly important point as the in vivo models so far have only included zebra fish and 
murine models. In the context of lung cancer these models are not translatable. The best models 
will be the use of ovine (sheep) since their lung size are the most comparable to humans. To 
supplement this, ex vivo human lungs would also provide a powerful model. Considering this, 
the use of 3D cancer spheroids is likely to be a closer translation than using a xenographed 




primary lung cancer cells extracted from real patients this might also enable to the simulation 
of the tumour heterogeneity, again this is a more representative model as it can illustrate 
potential drug resistance that tumours can acquire. 
These robust NHC-Pd catalysts with a carboxylic acid can be readily converted to a stable 
active ester. This provides a handle for bioconjugation and offers applications for both specific 
cell targeting ligands and bioorthogonal prodrug activation. Overall, it presents a step forward 




Chapter 3 Cancer-targeting palladium catalysts 
3.1 Introduction 
3.1.1 Antibody drug conjugates overview 
Monoclonal antibodies (mAbs) have become an integral part of modern-day research and 
medicine since their discovery due to their high specificity and affinity for their target antigens. 
Over the past few decades the use of mAbs in disease therapeutics has increased and their use 
is often glamorised with analogy to the “magic bullet” concept proposed by Ehrlich and 
Metchnikoff since they can specifically target a biomolecule and induce a therapeutic effect. 
Monoclonal antibodies can impart a therapeutic effect though complement-dependent 
cytotoxicity or antibody-dependent cell-mediated cytotoxicity,79,80 with both requiring 
interaction with the host’s immune system. They can also have therapeutic effect by inhibiting 
the function of the target antigens, for example, trastuzumab, bevacizumab and ceruxitmab 
have such an effect.80,81 However, few monoclonal antibodies have significant therapeutic 
activity against cancer and in clinical trials most only increase patient survival rates by a few 
months.80,82 
To improve the therapeutic potency of mAbs and reduce the side effects of common 
chemotherapy drugs the two have been combined to create antibody-drug conjugates (ADCs). 
ADCs aim to overcome the issues of chemotherapy side effects by targeting the delivery of 
the drug to cells that present the target antigen i.e. the cancerous cells. Often these antigens 
are over-expressed receptors on the surface of cancer cells, and once bound to the cancer cell, 





Figure 3.1 Important design features of an antibody drug conjugate. 
There are currently three Food and Drug Administration (FDA) approved ADCs. 
Brentiuximab vedotin (Adcetris®)83 was the first ADC is be approved in 2011. Under an 
accelerated approval regulations for patients with relapsed or refractory CD30-positive 
Hodgkin’s lymphoma after autologous stem-cell transplantation (ASCT) or when multiagent 
chemotherapy was not an option.84 It is a CD30-targeting mAb coupled with a microtubule 
disrupting agent monomethyl auristatin E (MMAE). MMAE cannot be used a drug by itself 
due to its high toxicity. A cathepsin-cleavable linker was used to link the drug and antibody 
together, and after binding to the CD30 receptor and internalisation into lysosomes, cathepsin 
proteases cleave this linker. The release of MMAE arrests the cell cycle between the gap 2 
phase and mitosis, resulting in cell apoptosis.85 
The second was Ado-trastuzumab emtansine (approved in 2013, Kadcyla®).86 It is composed 
of the mAb trastuzumab, the drug Mertansine (also called DM1) with the two linked via a non-
cleavable thioether. DM1 is a maytansine derivative and binds tubulin, inhibiting its formation. 
Upon binding to the HER2 receptor, and internalisation it undergoes proteolytic digestion, 
releasing three molecules of maytansine within the cells. Furthermore, the binding of 
trastuzumab to the HER2 receptor blocks the HER2-mediated signalling pathway, triggering 
antibody-dependent cell-mediated cytotoxicity. 
The third approved ADC Inotuzumab ozogamicin (Besponsa®), was approved for the 
treatment of acute lymphoblastic leukaemia (ALL) by the FDA in 2017. The mAb targets 




hydrolysis, releasing a Calicheamicin. These examples demonstrate that ADCs have had 
clinical success and there are over 65 ADCs in clinical trials suggesting that more will soon 
become available.87–91  
When designing ADCs there are three key things to consider (see figure 3.1): 
1. The antibody of choice (including amino acid sites for potential drug conjugation). 
2. The type of linker to be used: cleavable or non-cleavable. 
3. The drug to be conjugated. 
 
3.1.2 Selection of antibody and labelling sites 
The choice of antibody depends on the tumour antigen. Ideally, the antigen would be localised 
to the cell surface to allow for selective ADC binding. In addition, the antigen should be 
overexpressed on the surface of cancers cells and minimally expressed on healthy cells. If 
ADCs are taken into healthy tissue this would result in off-target toxicity lowering the amount 
that reaches the cancerous tissue. For maximum release of the drug, the ADC needs to be 
endocytosed into the cell upon which the antibody is degraded and would result in the drug 
being released freely into the cell (Figure 3.2).  
 
Figure 3.2 ADC processing. The ADC binds to its target antigen on the cell surface. The ADC-
antigen complex is internalised into endosomes and then lysosomes. In the lysosome the antibody is 
digested by proteases, releasing the cytotoxic drug inside the cell. Adapted from reference 83. 
When attaching the cytotoxic drug to the antibody, the site of attachment is an important 




due to the nucleophilicity of the amine or thiol moieties (Figure 3.3).93 The numerous lysines 
can result in heterogeneous labelling of the ADC which results in pharmacokinetic variability 
and difficulty in purification. Homogeneous ADC mixtures can be produced by genetically 
engineering unnatural amino acids into the antibody structure for specific labelling (Figure 
3.3). Homogenous ADC mixtures compared to heterogeneous mixtures, have a higher stability 
and better activity in vivo.92,94,95 
 
Figure 3.3. Different ways which drugs can be loaded onto a monoclonal antibody. (A) Using native 
cystine residues after reduction of disulphide bridges. (B) Using engineered amino acids for highly 
specific labelling (C) Linkage through native lysine residues. Adapted from reference 87. 
When using lysines as a site for conjugation, the primary ε-amines can be easily reacted with 
N-hydroxysuccinamide (NHS) activated esters to form the stable amide bond with a number 
of commercial linkers based on this approch.96,97 However, it is estimated that there are 40 to 
80 available lysine residues on mAbs, and without any specificity of which sites are labelled, 
the number of ADC variations can reach millions once the degree of labelling is >5 i.e.(40 – 
80)5 and this explains why such heterogenous mixtures are impossible to purify to a single 
compound. 
Cysteine residues on antibodies are used to help maintain the quaternary structure of the 
antibody by linking the protein subunits together through disulphide bridges. It has been 
suggested that reducing these disulphide bridges rarely affects the function of the antibody.98 
Under controlled conditions, disulphide bridges can be reduced to provide reactive thiol 
groups whilst maintaining the overall structure of the antibody. Most often, the thiol is then 




e.g. reactions with haloalkanes, or activated disulphides. A major discussion point with 
maleimide chemistry is the ADCs have been reported as losing their payload through retro-1, 
4 additions initiated by existing thiols present in plasma.99 The hydrolysis of the succinimide 
ring is a potential method to circumvent the retro-1,4 addition chemistry, as the ring-opened 
product is more stable100,101 but gives two product regioisomers. 
3.1.3 The ADC linker 
The linkers used in ADCs can vary greatly and there are two main classes: cleavable and non-
cleavable.102,103 The choice is important as it can have effects on the pharmacokinetic 
properties, therapeutic index, overall antibody specificity and affects the overall strategy for 
drug choice. To deliver their drug payload, cleavable linkers often rely on high levels of 
reducing agents (such as glutathione), low pH, and enzymes. On the other hand, non-cleavable 
linkers are dependent on the mAb degradation upon internalisation into endosomes and 
lysosomes for their activity. This generates metabolites containing the active drug with or 
without a portion of the linker. These differences should be considered when creating the ADC 
and their potential effect on the overall characteristics of the therapy.104  
Non-cleavable linkers have the benefit over cleavable linkers of being more stable in plasma, 
and generally, non-cleavable linkers have lower off-target toxicity. Yelena et. al. synthesised 
an ADC that linked the monoclonal antibody huC242 (a humanised anti-MUC1 monoclonal 
antibody) to the drug DM1 via an N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC) linkage (Figure 3.4). This utilised a “non-cleavable thioether” linker and 
its toxicity was tested against the COLO 205 and Namalwa cells aimed at targeting the mucin 
glycoprotein (MUC1) which is overexpressed in these cell lines. This ADC was compared 
directly against huC242-DM1 (Figure 3.5) that utilised a disulphide cleavable linker. It was 
found that off-target toxicity caused by the by-stander effect was lower in xenograft tumour 





Figure 3.4 Top; Structure of huC242-SMCC-DM1. Bottom; Structure of huC242-DM1. 
There are a variety of cleavable linkers which exploit different types of chemistry. Hydrazone 
groups are semi-acid labile linkers designed to be stable in the body at pH 7.4 during 
circulation in the blood. Upon internalisation of the ADC into lysosomes the environment will 
be approximately pH 5.0. This lower pH will allow the linker to undergo hydrolysis and release 
the cytotoxic drug; BR96-Dox (Figure 3.5) is an example of this strategy. BR96 is a mAb 
which targets the Lewis-Y antigen. It was shown by Firestone that after binding to the target 
tumour cells, the ADC is endocytosed into lysosomes.105 In clinical trials BR96-Dox was 
found to not be associated with the typical side effect profile of native doxorubicin and could 
therefore increase the therapeutic window for treating antigen-expressing tumours.106,107 
However, in one study it was found that the hyrdazone linker was unstable with free drug 
being found prematurely released into the bloodstream108 raising questions about its potential 





Figure 3.5 Structure of BR96-Box with an acid labile hydrazone linker. 
Reducible linkers are another attractive proposition in ADC generation, because reduced 
glutathione in tumour cells can be up to 1000-fold higher than in normal cell cytoplasm.109 It 
has also been suggested that tumour cells contain more enzymes in the protein disulphide 
isomerase family, which may contribute to the reduction of disulphide bonds in tumour cellular 
compartments.109,110 A development analogous to the huC242-SPCC-DM1 is shown in Figure 
3.6 which made it to phase II clinical trials, indeed IMGN901 has shown promising results. It 
contains the highly potent maytansinoid attached to a novel CD56-binding monoclonal 
antibody.  
 
Figure 3.6 Structure of IMGN901 with a disulphide bridge to link maytansinoid to a monoclonal 
antibody. 
Enzyme cleavable linkers present one of the more attractive options since they take advantage 
of the numerous enzymes available in cells. Peptide-cleavable linkers are the most widely 
used, and the linkers are designed to be stable in blood circulation and then be cleaved by 
intracellular proteases such as cathepsin B.111 The linkers for cathepsin B centre around the 
use of valine-citrulline dipeptides and the phenylalanine-lysine (Phe-Lys) dipeptide linker. 




cleaveage.112 The best example of the dipeptide in the clinic is brentuximab vedotin 
(Adcetris®) shown in Figure 3.7.  
 
Figure 3.7 Structure of brentuximab vedotin with a valine-citrulline linker. 
There are several different linkers to choose from when creating an ADC. Each linker has its 
own pros and cons, but the choice will have a profound effect on the ADC and its viability in 
the clinic. The final factor to consider for ADCs is the drug which is attached to it. 
 
3.1.4 The drug choice 
The choice of drug is important as it is the primary method of killing and reducing tumour 
size. It is key to know what the drug’s mode of action is, and if there is known methods of 
resistance and its overall potency. Most drugs used in ADCs are highly potent cytotoxic agents 
which target either microtubule formation or DNA structures with the IC50 values in the 
nanomolar range. Typically, they’re too toxic to be administered alone. The highly toxic agents 
are preferred, because of their effectiveness in combination with mAbs which requires only a 
limited number of antigens on the surface of a cell. By combining with mAbs the therapeutic 
window and selectivity of these drugs may increase such that they are clinically viable. Despite 
the specificity of ADCs, only a fraction of an administered dose will reach the intracellular 
target. Other things to be considered are the chemical structure such that there are moieties for 
conjugation to the linker. There should be some water solubility and stability in blood plasma 
because of the way which ADCs are prepared and administered intravenously. 
Maytansines and dolstatin  analogues (Figure 3.8) target tubulin and fragment microtubules,113 




toxic effects on non-malignant tissue, that prevented dose escalaltion.115 Maytansine was also 
assessed in clinical trials in the 1970s, though during Phase II trials there were concerns of its 
off target effects on the central nervous system.116 
 
Figure 3.8 Structures of the cytotoxic drugs Maytansinoid and dolstatin 10. 
There are also drugs which target the minor groove of DNA. Duocarmycins, and 
calicheamicins which cause irreversible alkylation and lead to cell death. Duocarmycins are a 
class of compounds which target A-T rich regions of DNA; these compounds have progressed 
to clinical trials but, due to dose-limiting effects, dosages were too low to achieve anti-tumour 
activity.117,118 Recently a trastuzumab and duocarmycin ADC has been developed known as 
SYD985 which is currently being tested in clinical trials.119,120 
Calicheamicins bind to the DNA minor groove and cause double strand breaks but has narrow 
therapeutic indices and serious toxic effects.121,122 In 2017 the ADC , Inotuzumab ozogamicin 
(Besponsa®), was approved for the treatment of acute lymphoblastic leukaemia (ALL) by the 
FDA (Figure 3.9). The mAb targeted CD22 cell receptors and upon internalisation a hydrazone 





Figure 3.9 Structures of inotuzumab ozogamicin (Besponsa) with the calicheamicin highlighted 
(top), and the structure of the drug duocamycin A (bottom). 
There are a wide variety of features to consider when designing an antibody drug conjugate. 
Given the importance of finding new cancer therapies and excitement in the field around ADC 
numerous reviews have been published that consider all the aspects previously 
discussed,90,95,103,123,124 such that ADCs have come a long way, and possibly represent the next 
generation of cancer treatments. There also are other approaches for cancer therapy that can 
be taken that also use antibodies. One such approach is the antibody directed enzyme prodrug 
therapy (ADEPT). 
3.1.5 Antibody Directed Enzyme Prodrug Therapy (ADEPT)  
ADEPT125–127 was a popular concept due to its simplicity; a mAb is linked to an enzyme to 
create a conjugate. This conjugate binds to cell surface receptors that are overexpressed on 
cancerous cell but minimally expressed on healthy cells. After accumulation of the conjugate, 




conjugate, the prodrug is chemically activated by the enzyme. The active drug can now be 
taken up into cancer cells via small molecule mechanisms and cause cellular death. The overall 
effect is like that of ADCs, a cytotoxic drug is delivered with spatial control to cancer cells 
preferentially over healthy cells. This reduces side effect of the drugs and potentially allows 
for higher doses to be administered (Figure 3.10). 
 
Figure 3.10 The concept of antibody directed enzyme prodrug therapy. An antibody enzyme conjugate 
binds to an overexpressed receptor on a tumour. A prodrug is added to the system, and only at the 
tumour site will the prodrug be activated into the active drug derivative. The active drug would then 
be taken inside the tumour cells. 
The problem for ADEPT was that whilst some candidates made it to stage II clinical 
trials,125,126 they ultimately failed due to the immunogenicity of the treatment. The only 
conjugate to have been studied in a clinical setting used carboxypeptidase G2 (CPG2). This 
enzyme originates from the Pseudomous sp. and had no known human analogues, and 
catalyses the cleavage of reduced and non-reduced folates.128 This allowed specific prodrugs 
to be designed which would not be activated by the host’s own enzymes, thus increasing 
specificity. It was because this enzyme was non-human that an immunogenic response was 
elicited causing a halt to progression in clinical trials. This, in combination with the need for 
repeat dosages to sustain the therapeutic effect, ultimately led to the requirement of co-
administration of cyclosporine to suppress the immune response.129 
It is possible that this approach could be more powerful than ADCs as the linker would always 
be non-cleavable and once site specificity had been optimised this could be applied to a range 




Changing the enzyme to another catalytic entity could be the key to progressing this 
technology forward since the immunogenicity of the enzyme was the biggest issue. 
3.2. Chapter aims  
The aim of this chapter was the synthesis an antibody palladium-catalyst conjugate capable of 
binding to cells and activating fluorophores (Figure 3.11). The considerations that were made 
for the generations of ADCs also need to be considered in this antibody-palladium conjugate.  
First a model system would be used to test the conjugation strategies with fluorophores. BSA 
would be used as a protein initially and carboxyfluorescein-NHS to test amide bond formation 
on the proteins. Following this, strained alkyne molecules could be added via the NHS-
conjugation (based on the result from the carboxyfluorescein-NHS conjugation). Then a 
fluorescein azide could be attached via strain promoted azide alkyne cycloaddition (SPAAC). 
With the SPAAC synthesis established, an N-heterocyclic carbene Pd catalyst was conjugated 
using the same methodology. This mAb-Pd conjugate would then be tested for its catalytic 
activity. 
 
Figure 3.11 A mAb-Palladium conjugate binds to an over expressed receptor on the surface on a 
tumour cell. A pro-fluorophore is administered to the system and upon interaction with palladium, it 
is activated into a fluorescent derivative. The activation of the fluorophore at the cancer site would 





3.3.1 Synthesis and evaluation of palladium catalysts with 
bioconjugation handles 
Following the successful development of a methodology of palladium catalysts described in 
chapter 2. A small sub-library of palladium catalysts with bio-conjugation handles were 
synthesised. Based on the results from chapter 2, it was decided to use the NHC-Pd centre with 
a valine attached. This conferred catalytic activity whilst also providing stability (Figure 2.18, 
Figure 2.20 and Figure 2.21). The spacer separates the catalytic centre and the bioconjugation 
handle and the amino acid; amino hexanoic acid served this purpose. Finally, the handle was 
either lysine, glutamic acid or lysine-ε-azide. This provided either an amine, carboxylic acid 
or an azide group respectively for conjugation reactions. Using this methodology, the 
following three catalysts were synthesised (Figure 3.12). 
Figure 3.12 Structures of the catalytic units synthesised 19, 20 and 21. 
Of the catalysts, the most objectively interesting was the catalyst containing the azide (19). To 
date, it is the first catalyst which contains a catalytically active transition metal and an azide 
moiety within the same compound. There are examples of azide-transition metal complexes30 
however, these have not been used to catalyse reactions. Delightfully, the azide also tolerated 
microwave synthesis and palladium loading conditions as previously utilised, further 
enhancing the credentials of the synthetic route’s versatility.  
The three catalysts were all assessed for their catalytic activity, using both PROC-Rh 110 and 




carried out with 10 mol % of catalyst and 100 µM of the fluorophores in PBS overnight (Figure 
3.13). 
 
Figure 3.13 (A) PROC-Rh 110 activation by Pd catalyst (B) Pro-DCF activation by Pd-catalysts. 
(C) Fluorescence fold increase. For all experiments n = 3 and error bars represent standard deviation. 
All three catalysts (19, 20 and 21) were able to generate a 10-fold increase in fluorescence. 
However, this was significantly less than the increase shown by Pd(OAc)2, at the same mol % 




be highly active due to the valine, so these results were underwhelming and surprising. 
Nevertheless, it was shown in chapter 2 that NHC-Pd catalyst with longer amino acid chains 
had reduced catalytic activity compared to those with a single amino acid linker. Why exactly 
this happened is unclear, but these results are consistent with those found in chapter 2.  
It can be deduced from the results in Figure 3.13 is that all three catalysts (19, 20 and 21) were 
able to “switch-on” fluorescence. Knowing that the catalysts were active, they were tested for 
any potential cytotoxicity against cells. Cells were incubated for 24 h with each compound at 
0.1, 1, 10 and 100 µM. the negative control for cytotoxicity was simply regular DMEM media 
and the positive control for cytotoxicity was 100% DMSO. 
 
Figure 3.14 MTT analysis of 19, 20, 21 and PROC Rh-110 against HeLa cells. Cell were incubated 
with different concentrations of each catalyst. The positive control for cell death was 100 % DMSO.  
for all experiments n = 3 and error bars are the standard deviation. 
It can be seen from Figure 3.14 that the catalysts exhibited no cytotoxicity (up to 100 µM) 
compared to a positive control for cytotoxicity. Whilst this result was expected, it is worth 
noting that given these would be targeted to cancer cells a degree of toxicity might be tolerated 
or even beneficial in a clinical setting. 
19 was also tested to see if it could also carry out Suzuki-Miyaura coupling. 19 (0.1 mol %) 
was incubated with phenyl boronic ester (75 µmol) and iodobenzene (37.5 µmol) with caesium 
carbonate (75 µmol) in water/acetonitrile (1:1, 1 mL) (Scheme 3.1). The reaction was 






Scheme 3.1 Synthesis of biphenyl using iodobenzene and phenyl boronic acid and an NHC-Pd 
catalyst. 
 
Figure 3.15 Analytical HPLC analysis of Suzuki Coupling over time. The retention time of the 
catalyst is 3.1 min, with the retention of phenyl boronic ester at 3.0 min and iodobenzene at 
5.9 min. Pure biphenyl was measured as a reference and has a retention time of 6.1 min. 
Measurements taken at the 254 nm wavelength. 
After 24 h a new peak for biphenyl could be seen, with conversion (based on the reduction of 







Table 3.1 Conversion to 24 over time by measurement of 
reduction of 22 at 254 nm. 
Reaction time (h) 24 48 96 120 144 168 
Conversion (%) 30 50 70 80 90 >95 
 
This reaction shows that this type of cross coupling chemistry is possible with the catalysts 
and is also one of the first examples of a Suzuki-Miyaura coupling in water using a 
homogenous catalyst whereas previous examples have used heterogeneous catalysts. 
To conclude 19 catalysed both de-propargylation reactions and Suzuki-Miyaura couplings. 
These features mean that it could be a feasible catalyst to carry forward for protein conjugation 
experiments. However, should difficulties occur the other two catalysts could also potentially 





3.3.2 BSA modelling 
Within the field of protein conjugation there are a variety of strategies that can be used.102,124,130 
It was decided the first approach to conjugation would be by using free amines present on 
lysine residues on the protein. Whilst this type of labelling is non-specific, if a strained alkyne 
could be conjugated onto a protein (via an NHS-activated ester), this would allow subsequent 
specific labelling via SPAAC using compound 19. Therefore, so long as the initial 
conjugations via the NHS-ester did not inhibit protein function it could be a viable route of 
labelling (Figure 3.16).  
 
Figure 3. 16 Overall strategy for conjugating palladium onto a protein. 
 
To conjugate a pallidum catalyst on to an antibody a methodology was first devised using BSA 
as a model protein. To begin, the commercial fluorophore isomer mix 5(6)-carboxyfluorescein 
was converted into the active NHS esters using EDC and NHS (synthesised by Daniel 
Norman). It was chosen due to availability and low cost of materials. Given that the following 
reactions were to be used as a model for understanding protein conjugation techniques, the 
isomers were not separated. 
Initially BSA was reacted with the fluorescein-NHS ester (scheme 3.2). Using five equivalents 
of the fluorescein-NHS (0.2 mM), the solution was heated to 37 °C for 4 h. The excess 
fluorophore was removed using Amicon® centrifugal filters using a molecular weight cut off 
(MWCO) membrane of 10 kDa. The reaction was carried out at two different pHs; 7.0, and 





Scheme 3.2 Carboxyfluorescein coupling to BSA. 
 
Following purification of the products they were analysed by MALDI-TOF MS, SDS-PAGE 
and UV-Vis spectroscopy techniques to calculate the degree of labelling. 
 
Figure 3.17 (Left) SDS-PAGE (10 %) after Coomassie staining; (Right) SDS-PAGE under 
irradiation at 480 nm. Each lane represents the following: Precision Plus Protein Kaleidoscope TM 
standards, with 25 and 75 kDa labelled; (A) Pure BSA; (B) 25a from a reaction at pH 7.0; (C) 25b 
from a reaction at pH 8.0. 
An SDS-PAGE gel was run to check for the presence of protein and confirm fluorescent 
labelling had occurred (Figure 3.17). As can be seen from the Coomassie blue staining, BSA-
fluorophore conjugates are present, though the resolution is too low to see any increase in 
molecular weight. Illumination under 480 nm was more informative where the reaction carried 
out in both pH 7.0 (Lane B) and 8.0 (lane C) had a fluorescent band. The reaction at pH 8.0 







Figure 3.18 MALDI-TOF MS analysis of BSA reaction with fluorescein to generate 25. Native BSA 
is shown in black. 25a in blue; 25b in red (Using 2,5-dihydroxybenzoic acid as a matrix). 
With the confirmed isolation of 25a, the reactions were then analysed by MALDI-TOF MS 
(Figure 3.18). It can be seen the molecular weight increased upon the reaction at pH 7.0 
compared to the native BSA by around 600 g/mol. Since the molecular weight of the 
fluorophore added each time is approximately 344 g/mol this would suggest a degree of 
labelling of around 1.8 – 2. The reaction at pH 8.0 showed an increase in molecular weight of 
1100, suggesting that there is a degree of labelling of around 3.9 moles of fluorophore per 
mole of protein.  
One of the issues with using MALDI-TOF MS analysis is that the spectra tend to be broad due 
to the abundance of natural isotopes present the protein. This makes recording a precise 
measurement of the m/z subjective. Furthermore, the methodology means that there will be a 
heterogeneous mix of proteins labelled with different amounts of the fluorophore giving 
labelling ratios of 1:1, 2:1, 3:1 and 4:1 etc. Therefore, the degree of labelling will not likely be 
a whole number and accounts for this heterogeneity, as a result, the degree of labelling will be 
an average. To confirm the level of labelling two equations can be used from the calculation 




(𝟏) 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀) =  
𝐴280 − (𝐴𝑚𝑎𝑥 × 𝐶𝐹)
𝜀
 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Equation 3.1. Equation used to calculate the protein concentration after conjugation with a 
fluorophore. Where A280 is the absorbance at 280 nm of the protein-fluorophore conjugate. Amax is 
the absorbance value at the maximum absorbance wavelength of the fluorophore (for example FAM 
= 492 nm). CF is the correction factor (correcting for the absorbance of the fluorophore at 280 nm). 
ε is the molar extinction coefficient of the protein and the dilution factor is any dilution applied to 
the sample. 
(𝟐) 𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑑𝑦𝑒 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 =
𝐴𝑚𝑎𝑥  𝑜𝑓 𝑡ℎ𝑒 𝑙𝑎𝑏𝑒𝑙𝑙𝑒𝑑 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝜀′ × 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀)
 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Equation 3.2. Equation to calculate the degree of labelling (DoL) from using equation 3.1. “Amax of 
the labelled protein” is the absorbance value at the maximum absorbance wavelength of the 
fluorophore; ε' is the molar extinction coefficient of the fluorophore; Protein concentration (M) is 
found from Equation 3.1.; Dilution factor is any dilution that may have been applied to the sample. 
The ε values for the fluorophore and BSA at 280 nm are 68,000 cm-1 M-1 and 43,824 cm-1 M-1 
respectively. The degree of labelling calculated from these values are shown in Table 3.2. 
 
Table 3.2 Absorbance values of products 25a and 25b used to determine the degree of 
labelling based on equations 3.1 and 3.2. 
Reaction 
(product) 
Absorbance at 280 nm Absorbance at 492 nm Degree of 
labelling 
(average) 
pH 7.0 (25a) 0.94 1.42 1.8 
pH 8.0 (25b) 0.87 1.87 3.9 
 
The degree of labelling for the reactions at pH 7.0 and 8.0 are 1.8 and 3.9 respectively. These 
data are supported by the results from the MALDI-TOF MS analysis. Satisfyingly, these 
results support the theory that as the pH increases, the degree of labelling increases, since more 
lysine resides on the protein surface have been converted from NH3+ to NH2, thus making them 
available to react as nucleophiles. Based on the results, it was decided to keep the pH at 7.0 as 
this would be more beneficial to the proteins – increasing the pH could lead to denaturing 
effects. Secondly, it means that the pH of the labelling reactions can be adjusted if the degree 
of labelling needs to be increased in future experiments. Finally, it was also important not to 




environments and this would reduce the risk of modifying the protein at functionally sensitive 
sites. 
Following the success of fluorophore-labelling, a strained alkyne was then attached to BSA. 
Five equivalents of DBCO-NHS (0.2 mM) were reacted with BSA at pH 7.0 for 4 h at 37 °C.  
The excess DBCO-NHS was removed using Amicon centrifugal units, MWCO 10 kDa. And 
the reacted BSA-DBCO product 26, was concentrated to a final volume of 50 µL. A 5 µL 
sample was retained for analysis and the remaining solution diluted to 100 µL. To this, 5 
equivalents of commercial 5-FAM-N3 was added (0.2 mM). The solution was heated to 37 °C 
for 4 h, purified and concentrated as previously described to give 27 (BSA-DBCO-5-FAM). 
 
Scheme 3.3 BSA reaction with DBCO-NHS to give 26 and then cycloaddition with 5-FAM-N3. to 
give 27. 
  
Figure 3.19 SDS-PAGE gel of the reactions in scheme 3.3. (Left) Coomassie staining for proteins; 
(Right) gel exposed to 480 nm light prior to Coomassie staining. Lanes are as follows: Precision Plus 
Protein Kaleidoscope TM standards; (A): pure BSA; (B) 26; (C) 26 wash steps from purification; (D) 
27; (E) 27 wash steps from purification; (F) pure BSA mixed with 5-FAM-N3 control; (G) BSA-5-
FMA-N3 control wash from purification. 
 
From the SDS-PAGE gel (Figure 3.19), the reactions were clearly successful. Firstly, products 
26 and 27 were successfully isolated confirmed by the presence of bands in Lanes B and D 
and the absence of bands in lanes C and E. There also appears to be a small shift up the gel 




in Lane D also confirms the attachment of a fluorescent molecule. Reaction with BSA and 5-
FAM-N3 as a control did not result in a fluorescent band (lane F). This suggests that the bands 
in Lane D are due to the covalent bonds formed via SPAAC reactions  
 
Figure 3.20 MALDI-TOF MS analysis of the reaction from Scheme 3.3. Pure BSA is in black, 26 in 
blue and 27 in red. 
 
From the MALDI TOF MS analysis (Figure 3.20), a clear shift in the protein molecular weight 
could be seen. The product of the BSA-DBCO reaction gave an increase of molecular weight 
of 1200. Since the increase in molecular weight per DBCO added is approximately 300 g/mol, 
approximately 4 equivalents of DBCO were added to each mole of BSA. There was an 
observed increase in molecular weight of 1200 after the 5-FAM-N3 (458 g/mol) coupling, to 
give a degree of labelling of approximately 3 fluorophores per molecule of BSA, and showed 
that approximately 75 % of the available strained alkyne sites had reacted though the SPAAC 
reaction. The absorbance of 27 was measured at 280 nm (protein concentration) and 495 nm 
(wavelength of maximum absorbance of fluorescein) and used in equations 3.1 and 3.2 to give 






Table 3.3 Absorbance values and level of labelling of 27 used to determine the degree of 
labelling based on equations 3.1 and 3.2. 
Product  Absorbance at 280 nm Absorbance at 492 nm Degree of labelling 
(average) 
27 0.80 1.51 2.9 
 
Following the results of the experiments described, it was concluded that the methodology 
would be sound to attempt to label antibodies with fluorophores and then move onto attaching 
palladium to the antibody. However, the antibody-fluorophore conjugate had to be validated 





3.3.3 Labelling of Herceptin with a fluorophore 
With a successful simple strategy for labelling proteins using SPAAC the same methodologies 
were carried out on the antibody Herceptin; a clinically approved mAb used to treat breast 
cancer.131,132 Herceptin binds to the epidermal growth factor receptor (EGFR, also known as 
the Her2 receptor) and prevents receptor dimerisation. Consequentially, this prevents the 
epidermal growth factor (EGF) binding to the receptor (Figure 3.21) and as a result there is no 
downstream signalling to induce cellular growth and proliferation. Herceptin was chosen as a 
model antibody due to its availability and cost compared to other antibodies. 
 
Figure 3.21 Overview for Herceptin function. Herceptin binds to the epidermal growth factor 
receptor (EGFR). Binding prevents dimerisation of the EGFR and thus prevents binding of the 
epidermal growth factor. This ultimately leads to the prevention of downstream signalling of cellular 
growth and proliferation. 
 
Firstly, Herceptin was reacted with 5 equivalents (0.2 mM) of DBCO-NHS at 37 °C for 4 h. 
The excess DBCO-NHS was removed using Amicon centrifugal spin units (MWCO 10 kDa). 
28 was then incubated with 5 equivalents of 5-FAM-N3 (0.2 mM) at 37 °C for 4 h and then 





Scheme 3.4 Attachment of fluorescein to Herceptin via the SPAAC reaction using DBCO as the 
strained alkyne to make 28a and followed by 5-FAM-N3 to give 29. 
 
As before, the reactions were analysed by SDS-PAGE, MADI-TOF MS and UV-Vis 
absorbance. It can be seen clearly from the SDS-PAGE (Figure 3.22) that Herceptin has been 
successfully labelled. Products 28a and 29 were both isolated successfully as shown on the 
Coomassie stained gel (Figure 3.22). Comparing lanes, A and C it can be seen the band at 25 
kDa in Lane C is slightly higher suggested that conjugation has increased molecular weight. 
Most tellingly, in the fluorescent image of the same gel (Figure 3.22). Only 29 in lane C had 





Figure 3.22 Labelling of Herceptin with a fluorophore (Scheme 3.4) analysed by SDS-PAGE (Left) 
Coomassie staining. (Right) Gel imaged under 480 nm light prior to Coomassie staining. Lanes are 
as following; Kaleidoscope ladder with key markers identified; (A) Pure Herceptin; (B) 28a; (C) 29. 
 
Next, the conjugates were analysed by MALDI-TOF MS (Figure 3.23). From the data it can 
be seen there was an average increase in molecular mass of 1000 Da between the native 
Herceptin and product 28a. This suggests that there are approximately 3 equivalents of DBCO 
added to Herceptin (300 da per DBCO molecule). After the addition of 5-FAM-N3 to 28a to 
give 29, the increase in molecular weight was approximately 1200 from 146000 to 147200 
(458 g/mol per fluorophore). This suggested that there is an average degree of labelling of 2.5 




Figure 3.23 MALDI-TOF MS analysis of the reactions from Scheme 3.4. Unmodified 
Herceptin is in black; 28a is in blue; 29 in red. 
 
Finally, the Herceptin product 29 was analysed by absorbance to determine the degree of 
labelling (Table 3.4). The ε values for the fluorophore and Herceptin at 280 nm are 68,000 cm-
1 M-1 and 210000 cm-1 M-1 respectively. 
Table 3.4 Absorbance values and level of labelling of 29 used to determine the degree of 
labelling based on equations 3.1 and 3.2. 
Product Absorbance at 280 
nm 
Absorbance at 492 
nm 
Degree of labelling 
(average) 
29 1.41 0.97 2.7 
 
Having successfully labelled the antibody it was imperative to test if it had retained its binding 
functionality. Due to the number of lysine sites and the non-specific nature of the labelling 
technique, it needed to be confirmed that there wasn’t any labelling in the crucial binding site 
of the antibody (Figure 3.24). 
While it has been stated before, it is important to reiterate that because of the non-specific 




is an average of the whole sample; this is true for all previous and future experiments. 
Therefore, there will be some conjugates within the “product” that are only singularly labelled 
and some which may have up to 5 or even 10 labelling. This is important when we consider 
antibody binding functionality as the antibodies that have the lowest conjugation numbers (i.e. 
only 1 or 2 fluorophores per antibody) are most likely to have retained their binding 
functionality since the probability of labelling the binding site will be lower. Following this, 
the antibodies in the sample with the highest labelling numbers (5 and above) will also have 
the high probability of a fluorophore being conjugated at or near the binding site thus reducing 
or even inhibiting binding functionality. The issue with this is that when analysing 
fluorescence these antibodies will give off the highest signal. The top 20 % of the MALDI-
TOF peak may account for 50 % of the fluorescence in the sample. The conclusion from these 
points is that in a clinical setting the majority of antibody binding will be with the lowest level 
of labelling and thus the lowest fluorescent signals or lowest amount of palladium catalyst 
loaded assuming that binding is an analogue concept and not strictly “on/off”. Naturally, this 
issue could have major implications with imaging diseases in vivo. In addition, it could mean 
that the calculated binding affinity does not correlate with the degree of labelling i.e. that 
because only 70 % of the product population are binding to the target, the average degree of 
labelling of will likely be lower than that of the whole population. To assess binding, other 
assays could be used, for example an ELISA assay might be devised which can give a more 
definitive/quantitative analysis of the Kd. To check that even the most heavily labelled 
antibodies are binding a simple binding experiment that is then analysed by mass spectrometry 
might also be possible though this is just hypothetical. 
 
Figure 3.24 Labelling of the antibody. (Left) Desired labelling on the antibody on the heavy chains 
or the light chain. (Right) Undesired labelling with a fluorophore located in the binding site of the 
antibody which would impair function.  
 
Analysing the structure of the binding site, there were no lysine residues in or close to the 
binding site of the antibody (protein data bank code: 1N8Z).133 This implies that the risk of 




cancer cell lines; SK-BR-3 and MCF-7. Both cell lines express the EGFR receptor on to their 
cell surface, however the SK-BR-3 cells have a significant over-expression of the receptor 
compared with MCF-7 cells. Both cell lines were incubated with 29 for 4 hours at a range of 
concentrations, and the cells were washed and analysed by flow cytometry. 
 
Figure 3.25 Flow cytometry of cell lines incubated with 29. (Left) Incubation with MCF-7 cells. 
(Right) Incubation with SKBR-3 cells. Cell population colours are as follows; Grey, control cells 
with no antibody; blue, 0.1 nM of 29; Red, 1 nM of 29; Yellow, 10 nM of 29; Green 100 nM of 29. 
 
The flow cytometry data in Figure 3.25 shows that when 29 was incubated with the MCF-7 
cell line, there was no significant shift in the populations. This was true for all concentrations 
used (0.1 nM – 100 nM). Contrastingly, when 29 was incubated with the SKBR-3 cell line, 
there was a moderate shift in the population at 0.1 nM (approximately. 30 %), and a clear shift 
at 1 nM (>95 % compared to the control). Interestingly at 10 nM and 100 nM the cell 
population shifts were the same, this suggests that even at 10 nM, all available cell surface 
receptors have already been saturated with 29. This suggests that the Kd of 29 is within the 
same order of magnitude as the native drug Herceptin which the FDA states as 5 nM.134,135 
As discussed above the fact that the degree of labelling is an average does mean that this 
interpretation of the Kd is debatable. Whilst the antibodies with the lowest levels of labelling 
will likely be binding securely, the issue is with antibodies with higher levels of labelling 





These results suggest that the antibody had retained its binding ability (Figure 3.25) and 
pleasingly was found to be in the same order of magnitude as native Herceptin (>10 nM) 
however, as discussed earlier this is very much a crude measurement and should be suject to 
further testing. Overall, this suggested that this method of conjugation would be viable for 
attaching a palladium catalyst since the only change in methodology would be changing 5-
FAM-N3 for 19. 
 
3.3.4 Labelling of Herceptin with Palladium 
With the success of labelling Herceptin with a fluorophore the next step was to try and label 
Herceptin with a Pd catalyst. Following the previous methodologies described above, 19 was 
attached to Herceptin as follows. Pure Herceptin was incubated with 5 equivalents of DBCO-
NHS (0.2 mM) at 37 °C for 4 h as before to generate 28a. Then 5 equivalents (0.2 mM) of 19 
was then added to the 28a for 4 h at 37 °C and purified using the Amicon centrifuge units 
(Scheme 3.5) to give 30a. The conjugation was confirmed by MADLI-TOF MS, SDS-PAGE 






Scheme 3.5. Labelling of Herceptin with palladium via the SPACC. 
 
From the SDS-PAGE gel (Figure 3.26) it can be seen that the isolation and purification of 28a 






Figure 3.26 SDS-PAGE of Palladium coupling onto Herceptin. Kaleidoscope ladder. (A) pure 
Herceptin; (B) 28a; (C) 30a. 
 
From the MALDI-TOF MS spectra (Figure 3.27) it can be seen that Herceptin was 
successfully labelled with DBCO with results consistent with those seen in Figures 3.24 and 
3.25. The shift in molecular weight from 28a to 30a was 2000 Da. Since the molecular weight 
of 19 is 687 Da, this would suggest approximately 3 moles of 19 have been attached onto the 
antibody. It also suggests that close to 100 % of the available strained alkynes on 28a were 






Figure 3.27 MALDI-TOF MS analysis of the palladium conjugation to Herceptin. Unmodified 
Herceptin in black; 28a in blue; 30a in red. 
 
These analyses confirmed that the level of labelling was between 2.5-3 equivalents of 
palladium per antibody; consistent with the previous labelling experiments. It is assumed that 
the labelling will not have impaired the binding capabilities of the antibody based on the flow 
cytometry data previously discussed. Though to confirm this more complex biological assays 
would be required. At this stage it was of more importance to confirm that the antibody-
palladium conjugate 27 still retained its catalytic activity. Absorbance at 280 nm and ICP-MS 
confirmed concentration for protein and the presence of palladium, respectively in 30a (Table 
3.5).  
Table 3.5 Protein concentration (based on absorbance at 280 nm) and palladium content 

















30a 4.22 18.6  2.21 39.8 15.2 2.6 
 
With confirmation that palladium had been attached to Herceptin, it was then evaluated for its 




incubated with PROC-Rh 110 (Scheme 3.6). 3.3 µM of 30a was incubated with 100 µM of 
PROC-Rh 110 for 18 h at 37 °C, this equated to 10 µM of catalyst being in the reaction. This 
assumption was based on the MADLI-TOF MS data suggesting there are approximately 3 
moles of Pd per mole of Herceptin. 
 
Scheme 3.6 Activation of PROC-Rh 110 with 30a. 
 
Several experiments were set up for analysis. 19 (an NHC-Pd catalyst with an N3 moiety) was 
incubated with the PROC-Rh 110 substrate as a positive control. The native Herceptin 
antibody was incubated with PROC-Rh 110 as a control to ensure that it did not cause any 
activation of the substrate. Finally PROC-Rh 110 was incubated with no other additives as a 




































Figure 3.28 PROC-Rh 110 activation by palladium catalysts. Fluorescence readings were measured 
as a fold increase compared to the PROC-Rh 110 negative control which is represented as 1. 19 was 
reacted with the substrate as a positive control. Reactions were carried out at 37°C, for 18 h in PBS. 






Figure 3.28 shows that The Ab-Pd conjugate appeared not to be active compared to the control 
reactions. The fold increase was no higher than the substrate without any catalyst, and the 
positive control reaction shows that in theory the catalyst should have had an activity close to 
19 since the concentrations were equal (10 µM). The antibody by itself did not cause an 
increase in fluorescence. It was decided to incubate 19 with the antibody freely in solution to 
see if the antibody inhibits catalytic activity in any way without the conjugation steps. The 
concentration of Herceptin used in all the following reactions was 10 µM and the pro-
fluorophore at 100 µM. 
 
Figure 3.29 Incubation of Palladium with Herceptin in solution. Reaction 1, 19 with free Herceptin 
and PROC-Rh 110; Reaction 2, 19 and PROC-Rh 110 only. Reaction 3 is Herceptin and PROC-
Rh 110 (no Pd). Reaction 4 is PROC-Rh 110 only. Reactions were carried out at 37 °C, for 18 h in 
PBS. Pd concentrations are at either 100 µM, 50 µM, or 30 µM. PROC-Rh 110 at 100 µM. Herceptin 
was a concentration of 10 µM. n = 3 errors bars are standard deviation.  
 
These results (Figure 3.29) suggest that the presence of Herceptin alone reduced the catalytic 
activity of 19. This was consistent at a range of concentrations. There is no clear hypothesis 
as to why this reduction in activity is so drastic. It is possible that the catalyst has been 
inactivated by thiols on the protein surface, however other Pd-catalysts were shown to be 
active in DMEM and in cells in Chapter 2, so this would seem inconsistent. One possibility 
could be that the Pd centres are “stuck” onto the surface of the antibody through non-covalent 
interactions. This prevents access of the pro-fluorophore to the Pd centre thus reducing the 
activity. Another possibility is that the free amine and carboxylic acid groups on the protein 




on these results, it was decided that increasing the levels of palladium loading onto the 
antibody could help improve the catalytic efficiency. Should this also fail to confer catalytic 
activity other ideas would need to be explored such as extending the linker between the 
catalytic centre and the mAb.  
To increase the palladium loading on Herceptin, the antibody was reacted with DBCO-NHS 
to generate 28b and subsequently 19 to give 30b (Scheme 3.5). To increase the degree of 
labelling, 25 eq. (1 mM compared to 0.2 mM previously) of DBCO-NHS was used. After 
purification and isolation, 25 eq. of 19 were added. After the reactions the products were 
analysed by SDS-PAGE, MALDI-TOF and ICP-MS.  
 
Figure 3.30 SDS-PAGE gel of 28b and 30b. Lanes are as following; Kaleidoscope ladder with key 
markers identified; (A) Pure Herceptin; (B) 28b; (C) 30b. 
 
The SDS PAGE (Figure 3.30) showed distinct shifts in the protein bands when comparing 
lanes, A, B and C indicating increased molecular weight and thus conjugation. This is most 
easily seen with the antibody light chain at 25 kDa. When comparing lanes B and C there was 





Figure 3.31 MALDI-TOF MS of the reaction in Scheme 3.8. Pure Herceptin in black. 28b in blue. 
30b in red.  
 
The MALDI-TOF MS data (Figure 3.31) showed significant shifts in the m/z of products 28b 
and 30b. The shift from the native Herceptin after reacting with the strained alkyne DBCO 
was 3000 Da. Given that the increase is 300 g/mol per DBCO added this suggests that there 
are now 10 equivalents of the strained alkyne attached. The increase after the palladium was 
added was 7000 Da the molecular weight 19 is 687 Da, suggesting an increase of around 10-
11 catalysts per antibody. The peaks became very broad, highlighting the heterogenicity of 
antibody-conjugates produced. Once again Absorbance at 280 nm and ICP-MS were also used 
to confirm the protein concentration and the palladium content, respectively of 30b (Table 
3.6). 
Table 3.6 Protein concentration (based on absorbance at 280 nm) and palladium content 






















With confirmation of increased loading via MALDI-TOF MS and the palladium content 
confirmed via ICP-MS, this new conjugate (30b) was then assessed for its ability to activate 
PROC-Rh 110. The palladium catalyst was incubated with PROC-Rh 110 with 1 µM of 30b 







































Figure 3.32 Activation of PROC-Rh 110 with palladium catalysts. Reactions were carried out at 37 
°C, for 18 h in PBS. Pd concentration of 10 µM, PROC-Rh 110 at 100 µM. n = 3 error bars are 
standard deviation.  
 
The results in Figure 3.32 showed 30b did cause some increase in fluorescence with its higher 
levels of Pd. It is notable that even though the concentrations of palladium in the reactions 
with 30b and 19 are the same, the absence of the antibody conjugation (and thus the lack of 
inhibition of the catalyst) means that fluorescence output was higher for the reaction with 19. 
Regardless, this shows that the concept of a catalytically active Pd-antibody “ADC” is viable. 
The key issue is that the turn-over of these catalysts were very low and practically a higher 
turnover would be beneficial. It was therefore decided to try and increase the length of the 




3.3.5 Changing the spacer 
It was hypothesised that extending the spacer between the antibody and the palladium catalyst 
might allow the palladium to be more active. DBCO-PEG12-NHS was chosen as a spacer due 
to the PEG chains allowing for more hydrophilicity; important for clinical applications by 
improving aqueous solubility (Scheme 3.7). The reactions were carried out and products 
purified using the same conditions as previously described. To generate two products with 
different degrees of labelling.  
 
Scheme 3.7 Coupling of 19 onto Herceptin via DBCO-PEG12-NHS chemistry (DoL = degree of 
labelling). 
 
Initially, 5 Equivalents of DBCO-PEG12-NHS (0.2 mM) were added to Herceptin at 37 °C for 




purified using Amicon centrifugal spin columns to give 32a. To generate 31b and 32b the 
same procedure was carried out except using 25 equivalents (1 mM) of the reagent DBCO-
Peg12-NHS and 19. 
 
Figure 3.33 SDS PAGE gel of the reactions in scheme 3.9: (Left gel) Lanes are as follows; 
Kaleidoscope ladder with key markers identified; (A) Pure Herceptin; (B) 31a; (C) 32a. (Right gel) 
Lanes are as following; Kaleidoscope ladder with key markers identified; (A) Pure Herceptin; (B) 
31b; (C) 32b. 
 
The SDS-PAGE in Figure 3.33 shows that both 31a and 32a showed an increase in the 
molecular weight of the protein, reducing their mobility and causing them to appear higher up 
the gel. The bands also widened due to the heterogeneous nature of the products. The same 
can be also seen for products 31b and 32b. These shifts together with the MS analysis (Figure 
3.34 and Figure 3.35) clearly indicated that conjugation of the linker and the palladium catalyst 





Figure 3.34 MALDI-TOF MS of the reaction in Scheme 3.7. Pure Herceptin in black. 31a in blue 




Figure 3.35 MALDI-TOF MS of the reaction in Scheme 3.7. Pure Herceptin in black. 31b in blue 
and 32b in red. 
 
Further to the SDS-PAGE gels, the products were then analysed by MALDI-TOF MS (shown 
in Figures 3.34 and 3.35). Figure 3.34 shows that the increase in molecular weight was 2000 
from Herceptin to 31a (indicative to 2 molecules of DBCO-PEG attached) and then 




molecules of Pd per antibody. In figure 3.35, the MALDI-TOF analysis of 31b and 32b 
showed a molecular weight increase of about 9000 (for 31b) and then a further 10000 Da (for 
32b). Suggesting that an average of 9 DBCO-PEG12 molecules were added to the antibody 
with 10 molecules of Pd subsequently added. Finally, 32a and 32b were analysed by 
absorbance at 280 nm and ICP-MS to determine the protein concentration and palladium 
content respectively of 32a and 32b (Table 3.7). 
Table 3.7 Protein concentration (based on absorbance at 280 nm) and palladium content 



















32a 1.02 12.5 0.77 9.6 5.2 1.8 
32b 4.61 50.0 0.87 35.5 5.0 8.7 
 
The discrepancy between the number of DBCO-PEG12 (9) and Pd (10) molecules added is 
likely due to the heterogeneous nature of the conjugates. Since the MALDI peaks are so broad 
definition becomes more subjective. These new antibody conjugates were evaluated for their 












































Figure 3.36 Activation of PROC-Rh 110 with palladium catalysts. Reactions were carried out at 37 
°C, for 18 h in PBS. Pd concentrations were 10 µM, in all cases with PROC-Rh 110 at 100 µM. 
(antibody in the controls was also 10 µM). n = 3, error bars are standard deviation. 
 
The results of the fluorophore activation with the new antibody-Pd conjugates (32a and 32b) 
is shown in Figure 3.36 and compared to the negative control reactions with no Pd. 32a and 
32b showed a small increased in fluorescence (2-fold and 5-fold respectively). Comparable to 
the activity of conjugate 30b. This suggests changing the length of the spacer did not have a 
significant effect on improving the catalytic activity of the Pd-catalyst.   
Overall, these results show that Herceptin was successfully loaded with the palladium catalyst 
via the strained alkyne DBCO with a longer PEG spacer and it was possible to label Herceptin 
with different ratios by modifying the concentration of reagents used. When the Pd-Herceptin 
conjugates were incubated with PROC-Rh 110, there was some turnover compared to controls 
although this was the same as when the linker was shorter, and in both cases limited. At this 
point any potential immunoreactivity was not tested however, this would need to be done 
regardless of the level of labelling and would likely be carried out in a phase I clinical trial. 
Given the widespread use of Herceptin and the knowledge that these catalysts are not 





3.4 Conclusions and future work 
In conclusion, this work demonstrates that it was possible to conjugate a palladium catalyst 
onto an antibody, a world first. This was accomplished by first evaluating BSA as a model for 
establishing reaction conditions for conjugation of fluorophores to the proteins. Then 
translated to labelling Herceptin with a fluorophore using SPAAC chemistry. Vitally, this 
fluorescent-Herceptin conjugate could still bind to its target HER2 receptor on SK-BR3 cells. 
Finally, an N-heterocyclic carbene palladium catalyst was conjugated onto the antibody and 
then evaluated for its catalytic activity.  
This antibody-Pd conjugate was the first of its kind and represents a step forward in the field 
of targeted palladium catalysts. The first conjugate synthesised 30a was not catalytically 
active, however it was shown that simply the presence of the antibody decreases the catalytic 
efficiency of catalyst 19. The reduction in catalytic activity is likely to be related to the 
mechanism and potentially what the ligand Y is. As speculated in chapter two Y could be any 
number of ligands from the solution but could also be a moiety from within the same molecule 
(e.g. carboxylic acid or amine). Moreover, in the context of the Pd-antibody the proximity of 
amine and carboxylic acid groups (from lysine and glutamic acid residues respectively) found 
on proteins may also be the source of inhibition to the catalyst and go some way to explaining 
the results found in figure 3.29.  
Thus, there needs to be a thorough investigation into the reasons for why the addition of an 
antibody decreases the catalytic activity of catalyst 19. Such an investigation could include 
spiking the catalysts with a ligand that will bind strongly to the Pd atom, then analysis by mass 
spectrometry. The spiking could include a range of different ligands including imidazole 
(which binds strongly to metals), or small molecules to simulate amines or carboxylic acids. 
The subsequent “products” might be then analysed with other structural studies like X-ray 
crystallography (if possible) to see if these ligand are bound as well as assaying the catalytic 
activity of the palladium using previously described substrates. 
Initially other NHC-Pd synthesised in Chapter 2 could be tested to see if the presence of an 
antibody decreases their activity too. Moreover, different antibodies might have a less 
profound effect – this might be unlikely if the issue is cause by some general factor such as 
thiols or the protein structure.  
From the initial results, it was decided that increasing the level of palladium on the conjugate 
might improve the catalytic efficiency of the conjugate. Delightfully, this higher Pd loaded 




PROC-Rh 110 to the fluorescent product Rhodamine 110. One key limitation was that the 
conversion was lower than that of the free catalyst though this is somewhat mitigated by the 
findings that the antibody reduces activity even in solution. The analysis in this chapter lacked 
quantitative conversion analysis by techniques such as HPLC and it would be desirable data 
to support this work. However, in a clinical setting, low conversion may not matter if the 
reporter fluorophores are bright enough and there is a large enough signal-to-noise ratio. If 
higher conversion were needed one option would be to change the catalyst to one that 
demonstrated higher activity from Chapter 2. For example, the catalyst that had just a valine 
residue was both highly active and stable. Since all those catalysts had carboxylic acids they 
could be converted into active NHS-esters and be attached to proteins via and amide bond. 
Changing the catalyst might be preferable in future work anyway to allow for better catalytic 
responses to give greater control over clinical procedures.   
During this work different levels of palladium were loaded on to catalyst after their validation 
of the conjugation methodology. The linker between the catalyst and the protein was also 
varied to see if that this would have any effect on the catalytic activity, but in the end, it did 
not. In this work only 2 different linkers were explored, a short four-carbon chain and a longer 
PEG12 chain. With regards to improving the catalytic efficiency of the Pd-antibody conjugate 
other linkers could also be trialled, for example branched linkers might allow for a higher 
loading of the palladium catalysts and PEG might decompose the Pd. In this work the linkers 
tested had flexible chains, however having rigid linkers should also be explored to see if they 
help to improve catalytic efficiency. However, given the that the two options already explored 
did not cause any difference in the catalytic turnover, it suggests that the chemistry of the 
linker is not crucial. Ultimately, it is important that the linker is kept as a “non-cleavable” 
linker so that in clinical setting there would not be any undue loss of palladium before the 
conjugate reached its intended target.  
Extra research that might be of interest would be X-ray crystallography to determine the crystal 
structure of the Pd-antibody conjugate. This might be best attempted once a more consistent 
method of labelling has been created such that there is a homogenous product. A crystal 
structure would also be another way to validate that the conjugation of the Pd catalyst was not 
in any crucial binding site of the antibody.  
Once a Pd-antibody conjugate has been made which is sufficiently catalytically active, the 
next experiments would be to begin testing this type of system in vitro then in vivo using 
translatable models. Should those be successful however, the technology could be a basis for 




its catalytic activity and range of chemical reactions could also be used to switch on prodrugs 
such as those demonstrated at the end of Chapter 2 in the 3D cancer spheroid models. In a 
clinical setting it could be feasible to use one administration of an antibody-Pd conjugate, that 
could diagnose (using fluorescence activation) and treat the disease (pro-drug activation). The 
ligand developed could also be explored with other metals (for example Ru) or perhaps 
radioactive metals for alternative therapeutic approaches. Ultimately, with the range of 
antibodies available these bio-conjugatable catalysts could become a powerful platform 




Chapter 4 Thesis conclusions 
The original aims of this thesis were to: 
1. Develop a biocompatible catalyst which can be used to activate fluorescent probes in 
cancerous cells. 
2. Attach the catalyst to a biological targeting molecule such as an antibody. 
3. Test the ability of this targeted catalyst to generate fluorescent signals in translational 
models. 
The first aim was successfully achieved in Chapter 2, where a new synthetic methodology was 
used to create a library of biocompatible Pd catalysts. Not only was this methodology robust 
to generate a range of different catalysts, but also significantly reduced the time taken to 
synthesise them. The catalysts were shown to activate a caged fluorophore in biologically 
relevant conditions with 11 then used to activate a prodrug inside a 3D cancer spheroid model. 
This was important, as 3D cancer models are more representative than 2D when trying to 
replicate results in a clinical setting. These catalysts also had a carboxylic acid moiety which 
could be activated for conjugation purposes. 
The next aim was to attach Pd catalysts to a targeting molecule such as an antibody. Following 
the success in Chapter 2, Chapter 3 began with the synthesis of three more catalysts which had 
distinct handles for bioconjugation methods, with a particularly interesting catalyst containing 
an azide moiety. These were then successfully conjugated onto antibodies after model 
reactions were used to determine suitable conjugation reaction conditions. With a successful 
Pd-antibody conjugate, the first known, this conjugate was then tested for its ability to activate 
a caged fluorophore. It was only when the levels of palladium had been increased (from 3 to 
10 molecules of Pd per antibody) that catalytic activity was observed, though the turnover was 
disappointingly low. Moreover, changing the linker did not improve the activity of the 
conjugate. This leaves the chapter somewhat at a crossroads but leaves lots of potential to 
explore new avenues. These avenues include: 
1. Changing the catalyst for one which is more active. 
2. Find brighter/more responsive fluorophores so that minimal signals can be detected. 
This includes changing the fluorophores wavelengths to NIR that could be more 
clinically relevant. 
3. Design amplification probes that release multiple fluorophores so that one activation 




The third aim of this thesis was untimely not achieved, it would be the next step in the 
development of the Pd-Antibody conjugates in their pathway to the clinic. Looking forward 
once a more functionally viable Pd-antibody has been made, the first step would be to test its 
ability to activate caged fluorophore whilst its attached to cells. This activation could also 
include prodrugs to show enhanced cell death. Next the conjugate can be tested on 3D cell 
culture or ex vivo models that are more representative of lung cancer before potentially moving 
to in vivo models. The beauty of this design is that it could be highly transferable where the 
changing of the antibody could allow the same concept to be used to diagnose other cancers 





Chapter 5 Experimental 
5.1 General Experimental 
Amino acids, aminomethyl polystyrene resin and 2-chlorotrityl polystyrene resin were 
purchased from GL Biochem (Shanghai) Ltd and NovaBiochem, all other chemicals were 
from Sigma Aldrich, Acros and Fluorochem and used without purification unless otherwise 
stated. Solvent removal was carried out under reduced pressure on a Büchi rotary evaporator, 
or overnight in a Heraeus vacuum oven at 40 °C. PBS used was Dulbecco’s phosphate buffered 
saline. Dibenzocyclooctyne N-hydroxysuccinamide ester (DBCO-NHS), dibenzocyclooctyne-
polyethylene glycol N-hydroxysuccinamide ester (DBCO-PEG12-NHS) and 5-fluorescein 
azide (5-FAM-N3) were purchased from Jena Bioscience. Poly acrylamide SDS-PAGE gels 
10 % were purchased from Bio-Rad. Herceptin was purchased from Carbosynth (Berkshire) 
Ltd. 
1H and 13C NMR spectra were recorded on an automated Bruker AVA 500 (500 and 126 MHz 
respectively) in the indicated solvents at 298 K. Chemical shifts (δ) are quoted in parts per 
million (ppm) using the deuterated solvent as an internal standard and all coupling constants 
(J) were measured in Hertz (Hz). Resonances are specified as singlets (s), doublets (d), triplets 
(t), multiplets (m), broad singlets (br s) or aromatics (Ar). Low Resolution Mass Spectra 
(LRMS) were obtained using an Agilent LCMS 1100 ChemStation with a G1946B quadrupole 
mass detector. High Resolution Mass Spectra (HRMS) were performed on a Bruker 3.0 T 
Apex II spectrometer. All HRMS data is quoted in positive mode unless specified. All 
compounds have been reported as [M+H]+ though for many [M+Na]+ was also observed. 
MALDI-TOF mass spectra were obtained with a Bruker UltraflexExtreme MALDI TOF/TOF 
instrument and analysed using the Bruker Daltonics flexAnalysis software. All MALDI data 
was acquired in positive mode unless specified. Analytical RP-HPLC was performed on an 
Agilent 1100 Chemstation equipped with a Kinetex 5 µm XB-C18 100A (50 mm × 4.6 mm) 
column eluting with a gradient of water/formic acid (0.1 %) to MeCN/formic acid (0.1 %) 
over 10 minutes with a flow rate of 1 mL/min, with compounds detected by an ELS detector 
and a multi-wavelength detector. Preparative RP-HPLC purifications were performed on an 
Agilent Technologies HP1100 Chemstation eluting with water and MeOH (5 % MeOH to 95 
% over 25 min) with 0.1 % formic acid on a Kinetex 5 µm XB-C18 100A (150 mm × 21.2 
mm) column with a flow rate of 10 mL/min, or on an Eclipse XDB-C18 5 µm (9.4 mm × 250 
mm) column with a flow rate of 1 mL/min. Microwave assisted heating was carried out in a 




apparatus from Bibby Scientific Ltd. Absorbance and fluorescence spectra were obtained 
using either a Shimadzu RF-6000 spectrofluorometer, or a Synergy Biotek plate reader and 
analysed using the Gen5 software. Fluorescent kinetic assays were read on a BioTek synergy 
HT plate reader. Absorbance values for protein conjugates were measured on a Thermo 
Scientific NanoDrop 2000c.   
ICP-MS Pd content were obtained on an Agilent 7500ce ICP-MS suitable for the trace analysis 
of metals between 0.001-10.0 ppb. Gel electrophoresis was carried out on buffered gels and 
analysed on a Bio-Rad Gel Doc XR+ system and analysed on Image Lab V6 software. Flow 
cytometry was carried out on a Becton Dickinson (BD) FACSAriaTM and analysed using the 
FlowJo software (version 7.2.4). Confocal images were obtained on a Leica SP5 confocal 





5.2 Solid phase synthesis 
Resin Activation 
2-Chlorotrityl polystyrene resin (300 mg, 1 mmol/g) was swollen in dry DCM for 30 min and 
drained. To the resin, a solution of thionyl chloride (2.5 eq.) in DCM (3 mL) was added. The 
resin was shaken for 1 hour before being drained and washed with dry DMF (3 × 5 mL) and 
dry DCM (3 × 5 mL). 
First amino acid couplings 
All amino acids and linkers were coupled according to standard Fmoc SPPS protocols. 
Quantities were based on the use of 300 mg of resin (1 mmol/g loading). 
For coupling to 2-chlorotrityl linker, the first appropriate amino acid (1 mmol) was dissolved 
in dry DMF (3 mL). To this, DIPEA (314 µL, 1.8 mmol) was added and the mixture was added 
to the resin and shaken for 1 h before being drained and washed with DMF (3 × 5 mL) and 
DCM (3 × 5 mL) and MeOH (3 × 5 mL). The resin was then capped with a mixture of 
DCM/MeOH/DIPEA (80:15:5) for 10 min (2 × 3 mL). 
For aminomethyl polystyrene resin (300 mg 0.675 mmol/g), Fmoc Rink linker (5 eq., 1 mmol) 
was dissolved in DMF (3 mL) and mixed with Oxyma (5 eq., 1 mmol) for 5 min. To this, DIC 
(5 eq., 1 mmol, 157 µL) was added and mixed for 5 mins further. The solution was added to 
the resin and stirred for 2.5 h. The resin was then washed with DMF (3 × 5 mL), DCM (3 × 5 
mL) and MeOH (3 × 5 mL). 
Fmoc deprotection 
Pre-swollen peptidyl resin (300 mg, 1 mmol/g) was treated with piperidine in DMF 20 % (v/v) 
(2 × 10 min) and washed with DMF (3 × 5 mL) and then DCM (3 × 5 mL). 
Subsequent amino acid couplings 
Appropriate Fmoc-protected amino acids (5 eq., 1 mmol), were dissolved in DMF (3 mL) and 
mixed with Oxyma (5 eq., 1 mmol) for 5 min. To this, DIC (5 eq., 1 mmol, 157 µL) was added 
and mixed for 5 min further. The solution was added to the resin and stirred for 45 min. The 






Bromoacetic acid coupling 
The resin (300 mg, 1 mmol/g) was washed with DMF (2 × 5 mL) and a solution of bromoacetic 
acid (830 mg, 6 mmol) and DIC (460 µL, 3 mmol) in DMF (3 mL), pre-mixed for 20 s, was 
added. The mixture was heated under microwave irradiation in an SP Wave (Biotage) for 20 
min at 60 °C. The resin was subsequently washed with DMF (3 × 5 mL), and DCM (3 × 5 
mL).  
Imidazole coupling 
To resin (300 mg, 1 mmol/g) washed with DMF (2 × 5 mL), a solution of imidazole (413 mg, 
6 mmol) in DMSO (2 mL) was added and shaken for 5 min. A solution of AgNO3 (254 mg, 
1.5 mmol) in DMSO (1 mL) was added. The mixture was heated under microwave irradiation 
in an SP wave for 40 min at 60 °C. The resin was subsequently washed with DMF (3 × 5 mL), 
and DCM (3 × 5 mL).  
Imidazole alkylation coupling 
To resin (300 mg, 1 mmol/g) washed with DMF (2 × 5 mL) trimethylamine (139 µL, 1 mmol) 
was added followed by a solution of 2-bromomethyl pyridine (759 mg, 3 mmol) in DMF (2 
mL) and shaken for 5 min. A solution of AgNO3 (254 mg, 1.5 mmol) in DMF (1 mL) was 
added and shaken for 2 min. The mixture was heated under microwave irradiation in an SP 
wave for 90 min at 60 °C. The resin was subsequently washed with DMF (3 × 5 mL), then 
piperidine in DMF 20 % (v/v, 3 × 5 mL) and DCM (3 × 5 mL).  
Palladium loading to ligands on resin 
Resin (300 mg, 1 mmol/g) was swollen for 30 min under Ar in anhydrous DCM. The resin 
was then washed with anhydrous DMF (2 × 5 mL) under Ar. The resin was swollen with a 
minimal amount of anhydrous DMF after which 2-tert-butylimino-2-diethylamino-1,3-
dimethylperhydro-1,3,2-diazaphosphorine (173 µL 0.6 mmol) was added and stirred for 30 
min under Ar. The solution was then removed and dichloro(1,5-cyclooctodiene)palladium 
(127 mg, 0.45 mmol) in anhydrous DMF (1 mL) was added to the resin and stirred overnight 
under inert atmosphere at room temperature. The resin was washed with DMF (2 × 5 mL) and 
DCM (2 × 5 mL) and 95 % TFA/DCM was added for 2 h to cleave the product. The solution 
was drained from the resin and the solvent was removed under reduced pressure. The crude 





5.3.1 Solution synthesis 
tert-Butyl (imidazol-1-yl)acetate 2 
 
Glyoxal (40 wt% solution in water, 580 mg, 10 mmol) and formaldehyde (37 wt% solution in 
water, 300 mg 10 mmol) in i-PrOH (10 mL) were added dropwise to a stirred solution of 
glycine tert-butyl ester hydrochloride (1.68 g, 10 mmol), ammonia (28 wt% solution in H2O, 
11 mmol, 552 µL) and i-PrOH (35 mL). After complete addition the reaction was heated to 80 
°C overnight. The dark red solution was allowed to cool to room temperature and diluted with 
DCM (25 mL). The organic layer was separated, washed with NaOH (1.0 M, 25 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The crude was purified by silica gel column 
chromatography (ethyl acetate/hexane = 4:1, then DCM/methanol = 19:1). Purification was 
monitored by thin layer chromatography, to yield a yellow solid (703 mg, 3.8 mmol), 39 %.  
Mp 110-112 °C; 1H NMR (500 MHz, CDCl3): δ ppm 7.48 (1H, s), 7.08 (1H, t, J = 1.1), 6.94 
(1H, t, J = 1.3), 4.58 (2H, s), 1.47 (9H, s); 13C NMR (126 MHz, CDCl3): δ ppm 166.3 (C), 
137.8 (CH), 129.5 (CH), 119.8 (CH), 83.1(CH2), 48.7 (C), 27.9 (CH3); HRMS (ESI): 
calculated. for C9H15O2N2, 183.1128; found 183.1113 [M+H]+. Spectral data are consistent 




2-(Bromomethyl)pyridine hydrogen bromide (505 mg, 2 mmol) was added to a solution of 2 




under microwave irradiation. The solvent was removed in vacuo, and the crude was dissolved 
in DCM/TFA (1:1, 10 mL) and stirred for 2 h after which the solvent was removed in vacuo. 
The concentrated solution was dissolved in water and purified by preparative RP–HPLC to 
yield the title compound as a dark red oil (20 mg, 0.09 mmol, 5 %). 
1H NMR (500 MHz, CD3OD): δ ppm 9.10 (1H, s), 8.57 (1H, ddd, J = 4.9, 1.9, 1.0 Hz), 7.88 
(1H, td, J = 7.7, 1.8 Hz), 7.62 (1H, t, J = 1.8 Hz), 7.58 (1H, t, J = 1.8 Hz), 7.50 (1H, d, J = 7.8 
Hz), 7.40 (1H, ddd, J = 7.7, 4.8, 0.9, Hz), 5.58 (2H, s), 4.84 (2H, s); 13C NMR (126 MHz, 
CD3OD): δ 171.1 (C), 154.5 (C), 150.9 (CH), 139.2 (CH), 138.4 (CH), 125.2 (CH), 125.1 
(CH), 124.1 (CH), 123.4 (CH), 54.9 (CH2), 53.3 (CH2); HRMS (ESI): Calculated for 
C11H12O2N3, 218.0924; found 218.093 [M+H]+. Spectral data are consistent with the 
literature.73,136  
Bis-propargyloxycarbonyl-protected Rhodamine 110 (PROC-Rh 110) 
 
Rhodamine 110 (200 mg, 0.55 mmol) was dissolved in anhydrous DMF then cooled to 0°C. 
Propargyl chloroformate (129 µL, 1.1 mmol), and triethylamine (228 µL, 1.64 mmol) were 
added dropwise, followed by 4-dimethylaminopyridine (3.3 mg, 0.03 mmol). The cooled 
solution was allowed to warm to room temperature stirred for 24 h. The pink solution was 
dissolved in ethyl acetate (5 mL) and washed with 1 mM HCl (2 × 20 mL). The aqueous phase 
was then extracted with ethyl acetate (2 × 20 mL). The organic phase was washed and dried 
over MgSO4, filtered and concentrated. The resultant crude was purified by silica gel 
chromatography (hexane/ethyl acetate = 1:2) and monitored by thin layer chromatography to 
yield the title compound as a white solid (25 mg, 51 µmol, 9 %). 
 1H NMR δ (500 MHz, Chloroform-d): 8.02 (1H, d, J = 7.5 Hz), 7.66 (1H, td, J = 7.4, 1.1 Hz), 
7.62 (1H, td, J = 7.5, 1.1 Hz), 7.51 (2H, s), 7.13 (1H, dt, J = 7.6, 1 Hz), 6.96 (2H, dd, J = 8.6, 
2.2 Hz), 6.78 (2H, br s), 6.73 (2H, d, J = 8.6 Hz), 4.80 (4H, d, J = 2.5 Hz), 2.53 (2H, t, J = 2.5 
Hz); 13C NMR (126 MHz, Chloroform-d): 169.5 (C × 2), 153.3 (C × 2), 152.2 (C × 2), 152.0 




114.5 (CH × 2), 106.7 (CH × 2), 82.2 (C × 2), 75.5 (CH2 × 2), 53.2 (CH2 × 2); Rf 
(EtOAc:hexane, 2:1) = 0.76; m/z (LC/MS ESI, MeCN) 495.1 [M+H]+. Spectral data are 
consistent with the literature.62 HPLC was used to confirm lack of peaks at 495 nm indicating 
no fluorescence material was in the product which could generate false positive results in 
fluorescence studies. ELS and 254 nm channels were also checked to assess purity by 
integration of peaks.  
5.3.2 Ligands for palladium catalysts 
The following section contains characterisation data of compounds 8, and 33 to 43. These 
compounds are the ligands to which palladium was subsequently added. As a result, they were 
not explicitly described in the main text but their characterisation prior to palladium loading 
was vital. 
Each compound was synthesised according to the general methodologies described in Section 
5.2 (Solid phase synthesis). All were synthesised on a resin scale of 300 mg, using either a 2-
chlorotrityl (8 and 33-39) or Rink linker (39-43) on polystyrene resin. Samples of each ligand 
were cleaved off the solid support with 30 % HFIP in DCM (for 2-chlorotrityl linker) or 95 % 
TFA in water (for Rink linker) and purified by semi-preparative RP-HPLC (unless otherwise 
specified). Formate counterions are from purification by HPLC systems and their peaks can 
be seen in NMR spectra as shown in chapter 2. Where no counter ion was clearly found 
through any analysis (MS or NMR) the compound has been shown in its zwitterionic form. It 
is possible that other counter ion are possible such as Bromide ions (originating from synthesis 
reagents used) or TFA ion from resin cleavage protocols. 
“Purity by HPLC” was measured by ELS detection and 254 nm wavelength detector unless 
otherwise specified. ELS detection was used to check for any impurities while the major peak 
at 254 nm was then integrated against all other peaks found in the system (at 254 nm). This 
peak was then confirmed as the product by NMR and mass spectrometry. All HRMS data was 










Purity by HPLC: 96 %; Yield: 65 %; 1H NMR (500 MHz, Methanol-d4): δ 8.58 (1H, d, J = 
4.8 Hz), 7.93 – 7.85 (1H, m), 7.68 (1H,  d, J = 1.6 Hz), 7.63 (1H, d, J = 1.6 Hz), 7.51 (1H, d, 
J = 7.8 Hz), 7.42 (1H, dd, J = 7.5, 4.9 Hz), 5.58 (2H, s), 5.02 (2H, s), 3.26 (2H, t, J = 6.8 Hz), 
2.22 (2H, t, J = 7.2 Hz), 1.67 – 1.51 (4H, m), 1.44 – 1.34 (2H, m); 13C NMR (126 MHz, 
Methanol-d4): δ 180.5 (C), 169.9 (C), 154.2 (C), 151.0 (CH), 139.2 (CH), 125.2 (CH), 125.1 
(CH), 124.1 (CH), 123.8 (CH), 54.9 (CH2), 51.9 (CH2), 40.6 (CH2), 37.1 (CH2), 29.7 (CH2), 
27.5 (CH2), 26.4 (CH2); HRMS (ESI): calculated 331.1765 for C17H23O3N4; found 331.1748 
[M+H]+; HPLC: tR 2.7 min (254 nm).  
3-[2-[(Carboxymethyl)amino]-2-oxoethyl]-1-(2-pyridinylmethyl)-1H-imidazolium 33 
  
Purity by HPLC: 91 %; Yield: 57 %; 1H NMR (600 MHz, Methanol-d4): δ 9.19 – 9.13 (m, 
1H), 8.58 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.89 (td, J = 7.7, 1.8 Hz, 1H), 7.69 (t, J = 1.9 Hz, 
1H), 7.64 (t, J = 1.8 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.42 (ddd, J = 7.7, 4.9, 1.1 Hz, 1H), 
5.57 (s, 2H), 5.10 (s, 2H), 3.94 (s, 2H); 13C NMR (151 MHz, Methanol-d4): δ 179.9 (C), 169.8 
(C), 154.2 (C), 151.0 (CH), 139.5 (CH), 139.2 (CH), 125.3 (CH), 125.2 (CH), 124.1 (CH), 
123.8 (CH), 54.9 (CH2), 51.9 (CH2), 42.6 (CH2); HRMS (ESI) calculated 276.1217 for 







Purity by HPLC: 94 %; Yield: 62 %;  1H NMR (500 MHz, Methanol-d4): δ 8.60 – 8.54 (m, 
1H), 7.89 (td, J = 7.7, 1.7 Hz, 1H), 7.68 (d, J = 1.8 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.51 (d, 
J = 7.8 Hz, 1H), 7.42 (dd, J = 7.3, 5.1 Hz, 1H), 5.57 (s, 2H), 5.02 (s, 2H), 3.28 (d, J = 6.8 Hz, 
2H), 2.29 (t, J = 7.3 Hz, 2H), 1.83 (m, 2H); 13C NMR (126 MHz, Methanol-d4): δ 179.4 (C), 
169.5 (C), 154.2 (C), 151.0 (CH), 139.2 (CH), 125.3 (CH), 125.1 (CH), 124.2 (CH), 123.9 
(CH), 54.9 (CH2), 51.9 (CH2), 40.7 (CH2), 34.3 (CH2), 26.2 (CH2); HRMS (ESI) calculated 




Purity by HPLC: 96 %; Yield: 46 %; 1H NMR (500 MHz, Methanol-d4): δ 8.57 (d, J = 4.2 
Hz, 1H), 7.89 (td, J = 7.7, 1.7 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.51 
(d, J = 7.8 Hz, 1H), 7.45 – 7.38 (m, 1H), 5.58 (s, 2H), 5.03 (s, 2H), 3.25 (t, J = 6.9 Hz, 2H), 
2.23 (t, J = 7.4 Hz, 2H), 1.65 – 1.57 (m, 2H), 1.57 – 1.50 (m, 2H), 1.40 – 1.30 (m, 6H); 13C 
NMR (126 MHz, Methanol-d4): δ 179.9 (C), 169.8 (C), 154.3 (C), 151.1 (CH), 139.2 (CH), 
125.3 (CH), 125.1 (CH), 124.1 (CH), 123.9 (CH), 54.9 (CH2), 52.0 (CH2), 40.8 (CH2), 36.7 
(CH2), 30.2 (CH2), 30.1 (CH2), 29.9 (CH2), 27.6 (CH2), 26.6 (CH2); HRMS (ESI) calculated 








Purity by HPLC: 92 %; Yield: 51 %; 1H NMR (500 MHz, Methanol-d4): δ 8.57 (1H, d, J = 
5.0 Hz), 7.92 – 7.85 (1H, m), 7.67 (1H, d, J = 1.6 Hz), 7.63 (1H, d, J = 1.5 Hz), 7.50 (1H, d, J 
= 7.7 Hz), 7.44 – 7.38 (1H, m), 5.56 (2H, s), 5.15 – 5.04 (2H, m), 4.25 (1H, d, J = 4.7 Hz), 
2.31 – 2.21 (1H, m), 0.96 (6H, dd, J = 7.3, 1.2 Hz); 13C NMR (126 MHz, Methanol-d4): δ 
177.7 (C), 169.2 (C), 154.3 (C), 151.0 (CH), 139.2 (CH), 125.3 (CH), 125.1 (CH), 124.1 (CH), 
123.7 (CH), 61.7 (CH), 54.9 (CH2), 52.1 (CH2), 32.0 (CH), 20.1 (CH3), 18.0 (CH3); HRMS 
(ESI) calculated 318.1686 for C16H22O3N4; found 318.1686 [M+H]+; HPLC tR 2.7 min (254 
nm).  
 
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazolium-3-yl]acetyl]-L-phenylalanine formate 37 
 
Purity by HPLC: 93 %; Yield: 36 %; 1H NMR (500 MHz, Methanol-d4): δ 8.60 – 8.53 (1H, 
m), 7.88 (1H, td, J = 7.7, 1.8 Hz), 7.63 (1H, d, J = 2.0 Hz), 7.51 – 7.46 (2H, m), 7.41 (1H, dd, 
J = 7.6, 4.9 Hz), 7.28 – 7.21 (4H, m), 7.20 – 7.12 (1H, m), 5.54 (2H, s), 4.99 (1H, d, J = 16.2 
Hz), 4.88 (1H, d, J = 16.4 Hz), 4.55 (1H, dd, J = 9.3, 4.3 Hz), 3.29 – 3.27 (1H, m), 2.92 (1H , 




151.0 (CH), 139.7 (CH), 138.0 (C) 130.4 (CH), 129.2 (CH × 2), 127.4 (CH × 2), 125.3 (CH), 
124.9 (CH), 124.1 (CH), 123.7 (CH), 57.8 (CH), 54.9 (CH2), 52.1 (CH2), 39.3 (CH2); HRMS 




Purity by HPLC: 93 %; Yield: 32 %; 1H NMR (500 MHz, Methanol-d4): δ 9.18 – 9.15 (1H, 
m), 8.60 – 8.55 (1H, m), 7.89 (1H, td, J = 7.7, 1.8 Hz), 7.70 (1H, t, J = 1.8 Hz), 7.63 (1H, t, J 
= 1.8 Hz), 7.53 – 7.50 (1H, m), 7.43 – 7.40 (1H, m), 5.58 (2H, s), 5.12 (2H, s), 4.46 – 4.39 
(1H, m), 2.93 (2H, t, J = 7.7 Hz), 2.01 – 1.90 (1H, m), 1.80 (1H, dt, J = 13.5, 7.5 Hz), 1.74 – 
1.65 (2H, m), 1.58 – 1.47 (2H, m); 13C NMR (126 MHz, Methanol-d4): δ 175.0 (C), 166.8 (C), 
154.2 (C), 151.0 (CH), 139.6 (CH), 139.2 (CH), 125.3 (CH), 125.1 (CH), 124.2 (CH), 123.9 
(CH), 54.9 (CH2), 54.0 (CH), 51.8 (CH2), 40.4 (CH2), 32.2 (CH2), 28.0 (CH2), 23.8 (CH2); 
HRMS (ESI) calculated 346.1873 for C17H24O3N5; found 346.1858 [M+H]+; HPLC 0.6 min 
(254 nm). 
N-[2-[1-(2-Ppyridinylmethyl)-1H-imidazolium-3-yl]acetyl]-L-phenylalanyl-L-





Purity by HPLC: 96 %; Yield: 37 %; 1H NMR (500 MHz, Methanol-d4): δ 8.56 – 8.54 (1H, 
m), 7.86 (1H, td, J = 7.7, 1.8 Hz), 7.65 (1H, d, J = 2.0 Hz), 7.55 (1H, d, J = 7.9 Hz), 7.49 (1H, 
d, J = 7.8 Hz), 7.40 (1H, d, J = 2.0 Hz), 7.40 – 7.37 (1H, m), 7.35 – 7.32 (1H, m), 7.28 – 7.16 
(5H, m), 7.11 – 7.05 (2H, m), 7.04 – 6.99 (1H, m), 5.54 (2H, s), 4.92 (2H, d, J = 3.7 Hz), 4.62 
(1H, dd, J = 9.1, 5.5 Hz), 4.57 (1H, t, J = 7.1 Hz), 3.21 – 3.15 (1H, m), 3.15 – 3.10 (2H, m), 
3.08 – 3.03 (1H, m), 3.00 – 2.95 (1H, m), 2.88 (1H, dd, J = 14.0, 9.2 Hz), 2.15 (2H, t, J = 7.4 
Hz), 1.49 (2H, p, J = 7.5 Hz), 1.31 – 1.20 (2H, m), 1.14 – 1.05 (2H, m); 13C NMR (126 MHz, 
Methanol-d4): δ 180.5 (C), 173.2 (C), 172.7 (C), 169.9 (C), 154.1 (C), 151.1 (CH), 139.2 (CH), 
138.0 (CH), 138.0 (C), 130.3 (CH × 2), 129.6 (CH × 2), 128.8 (C), 127.9 (CH), 125.3 (CH), 
124.9 (CH), 124.7 (CH), 124.1 (C), 123.8 (CH), 122.5 (CH), 119.8 (CH), 119.4 (CH), 112.4 
(CH), 110.7 (C), 56.7 (CH), 55.9 (CH), 54.9 (CH2), 51.4 (CH2), 40.3 (CH2), 38.6 (CH2), 37.1 
(CH2), 29.7 (CH2), 29.1 (CH2), 27.5 (CH2), 26.5 (CH2); HRMS (ESI) calculated 665.3310 for 
C37H43O5N7; found 665.3320 [M+H]+; HPLC tR 4.4 min (254 nm).  
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazolium-3-yl]acetyl]-L-phenylalanyl-L-valine-L-
glycine amide 40 
  
Purity by HPLC: 95 %; Yield: 75 %; 1H NMR (500 MHz, Methanol-d4): δ 9.10 (1H, t, J = 
1.6 Hz), 8.61 (1H, ddd, J = 4.9, 1.8, 1.0 Hz), 8.27 (1H, d, J = 7.7 Hz), 7.93 (1H, td, J = 7.7, 
1.8 Hz), 7.70 (1H, t, J = 1.8 Hz), 7.53 (1H, t, J = 1.8 Hz), 7.46 (1H, ddd, J = 7.7, 4.9, 1.1 Hz), 
7.34–7.30 (4H, m), 7.27 (1H, dd, J = 4.8, 3.8 Hz), 5.59 (2H, s), 5.08 (1H, d, J = 16.5 Hz), 5.01 
(1H, d, J = 16.6 Hz), 4.77 (1H, dd, J = 9.4, 5.4 Hz), 4.20 (1H, d, J = 2.4 Hz), 3.95 (1H, dd, J 
= 16.9, 5.2 Hz), 3.79 (1H, dd, J = 16.9, 5.3 Hz), 3.24 (1H, dd, J = 14.0, 5.4 Hz), 2.96 (1H, dd, 
J = 14.0, 9.4 Hz), 2.15–2.10 (1H, m), 1.00 (3H, d, J = 1.8 Hz), 0.98 (3H, d, J = 1.8 Hz); 13C 
NMR (126 MHz, Methanol-d4): δ 210.0 (C), 173.9 (C), 173.8 (C), 166.7 (C), 154.2 (C), 151.0 
(CH), 139.4 (CH), 139.2 (CH), 138.1 (C), 130.3 (CH × 2), 129.6 (CH × 2), 127.9 (CH), 125.3 




43.1 (CH2), 38.9 (CH2), 31.7 (CH), 19.7 (CH3), 18.8 (CH3); HRMS (ESI) calculated 520.2667 
for C27H34O4N7; found 520.2673 [M+H]+; HPLC; tR 3.3 min (254 nm). 
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazolium-3-yl]acetyl]-L-valine-(5-carboxypentyl)-
L-lysine(azide) amide 41 
 
Purity by HPLC: 95 %; Yield: 60 %; 1H NMR (500 MHz, Methanol-d4): δ 8.57 (1H, dt, J = 
4.7, 1.6 Hz), 7.89 (1H, td, J = 7.7, 1.7 Hz), 7.69 (1H, d, J = 2.0 Hz), 7.62 (1H, d, J = 2.1 Hz), 
7.51 (1H, dt, J = 7.8, 1.2 Hz), 7.42 (1H, ddd, J = 7.7, 4.9, 1.1 Hz), 5.57 (2H, s), 5.11 (2H, s), 
4.32 (1H, dd, J = 9.0, 5.2 Hz), 4.13 (1H, d, J = 7.1 Hz), 3.30 – 3.27 (2H, m), 3.19 (2H, td, J = 
6.9, 3.0 Hz), 2.25 (2H, t, J = 7.4 Hz), 2.07 (1H, h, J = 6.5 Hz), 1.85 – 1.77 (1H, m), 1.71 – 
1.57 (5H, m), 1.55 – 1.40 (4H, m), 1.39 – 1.31 (2H, m), 0.98 (6H, t, J = 6.4 Hz); 13C NMR 
(126 MHz, MeOD): δ 177.1 (C), 176.1 (C), 173.1 (C), 166.8 (C), 154.2 (C), 151.1 (CH), 139.2 
(CH), 125.3 (CH), 125.1 (CH), 124.2 (CH), 123.9 (CH), 60.9 (CH), 54.9 (CH2), 54.2 (CH), 
52.3 (CH2), 51.9 (CH2), 40.2 (CH2), 36.6 (CH2), 32.8 (CH2), 32.0 (CH), 30.0 (CH2), 29.5 
(CH2), 27.5 (CH2), 26.5 (CH2), 24.2 (CH2), 19.7 (CH3), 18.7 (CH3); HRMS ESI-MS calculated 
583.3463 for C28H43O4N10; found 583.3483 [M+H]+; HPLC; tR 2.6 min (254 nm).  
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazolium-3-yl]acetyl]-L-valine-(5-carboxypentyl)-





Purity by HPLC: 93 %; Yield: 61 %; 1H NMR (500 MHz, Methanol-d4) δ 8.60 (1H, dt, J = 
4.7, 1.3 Hz), 7.92 (1H, td, J = 7.7, 1.8 Hz), 7.72 (1H, d, J = 2.0 Hz), 7.66 (1H, d, J = 2.0 Hz), 
7.55 (1H, dt, J = 7.8, 0.9 Hz), 7.45 (1H, ddd, J = 7.7, 4.9, 1.1 Hz), 5.61 (2H, s), 5.18 (1H, d, J 
= 16.4 Hz), 5.14 (1H, d, J = 16.5 Hz), 4.36 (1H, dd, J = 9.4, 4.8 Hz), 4.18 (1H, d, J = 7.0 Hz), 
3.31 – 3.26 (1H, m), 3.19 – 3.13 (1H, m), 2.41 – 2.35 (2H, m), 2.27 (2H, t, J = 7.2 Hz), 2.16 – 
2.07 (2H, m), 1.98 – 1.88 (1H, m), 1.65 (2H, p, J = 7.3 Hz), 1.58 – 1.51 (2H, m), 1.42 – 1.33 
(2H, m), 1.01 (6H, dd, J = 6.8, 5.2 Hz); 13C NMR (126 MHz, MeOD) δ 184.6 (C), 176.9 (C), 
175.5 (C), 173.2 (C), 166.9 (C), 154.3 (C), 151.1 (CH), 139.2 (CH), 125.3 (CH), 125.2 (CH), 
124.2 (CH), 123.8 (CH), 61.0 (CH), 55.0 (CH2), 54.2 (CH), 51.9 (CH2), 40.2 (CH2), 36.6 
(CH2), 31.9 (CH2), 30.7 (CH2), 29.9 (CH), 28.9 (CH3), 27.3 (CH2), 26.4 (CH2), 19.7 (CH3), 
18.7 (CH3); HRMS ESI-MS calculated 558.3035 for C27H40O6N7; found 558.3042 [M+H]+; 
HPLC; tR 1.8 min (254 nm).  
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazolium-3-yl]acetyl]-L-valine-(5-carboxypentyl)-
L-lysine amide 43 
 
Purity by HPLC: 91 %; Yield: 66 %; 1H NMR (500 MHz, Methanol-d4): δ 8.60 (1H, dt, J = 
4.9, 1.4 Hz), 7.92 (1H, td, J = 7.7, 1.8 Hz), 7.72 (1H, d, J = 2.1 Hz), 7.65 (1H, d, J = 2.0 Hz), 
7.54 (1H, dd, J = 7.8, 1.2 Hz), 7.45 (1H, ddd, J = 7.7, 4.9, 1.2 Hz), 5.60 (2H, s), 5.15 (2H, d, 
J = 2.8 Hz), 4.36 (1H, dd, J = 8.8, 5.5 Hz), 4.17 (1H, d, J = 7.0 Hz), 3.25 (1H, dt, J = 13.8, 7.0 
Hz), 3.18 (1H, dt, J = 13.6, 7.0 Hz), 2.98 – 2.92 (2H, m), 2.28 (2H, t, J = 7.3 Hz), 2.11 (1H, h, 
J = 6.9 Hz), 1.93 – 1.81 (1H, m), 1.78 – 1.58 (5H, m), 1.57 – 1.43 (4H, m), 1.43 – 1.34 (2H, 
m), 0.98 (2H, d, J = 5.7 Hz) 0.97 (2H, d, J = 5.7 Hz); 13C NMR (126 MHz, MeOD): δ 176.9 
(C), 176.1 (C), 173.1 (C), 166.8 (C), 154.2 (C), 151.1 (CH), 139.2 (CH), 125.3 (CH), 125.1 
(CH), 124.2 (CH), 123.9 (CH), 60.92 (CH), 54.9 (CH2), 54.0 (CH), 51.9 (CH2), 40.51 (CH2), 
40.23 (CH2), 36.64 (CH2), 32.59 (CH2), 32.00 (CH2), 30.04 (CH), 28.17 (CH2), 27.58 (CH2), 
26.43 (CH2), 23.86 (CH2), 19.69 (CH3), 18.63 (CH3); HRMS ESI-MS calculated 557.3558 for 




5.3.3 Palladium catalysts 
The following Section describes the characterisation of the palladium catalysts synthesised. 
The catalysts were synthesised using the procedure outlined in Section 5.2. As in section 5.3.2., 
the purity by HPLC was analysed by ELS and 254 nm detection. The ELS confirmed the 
presence of no impurities such as salts or other non-UV absorbing molecules. The 254 nm 
detection confirm the product and its purity was calculated by the comparing the integral of 
the product peak against the integral of all other peaks observed. All HRMS data was acquired 
in positive mode and products are referenced as [M+H]+. For some compounds [M+Na]+ was 
also observed though has not be quoted. 
All the catalysts have been presented with an unspecified ligand “Y”. The identity of Y has 
been speculated in both chapters 2 and 3 and is likely to be one of the following: H2O, ACN, 
Cl-, Br-, Formate anion, TFA anion. These originate from the additives and solvent systems 
used during synthesis and purification and in PBS from biological studies. “Y” could also be 
a moiety from the same compound, for example the carboxylic acid or amine group that bends 
round to interact or from another molecule of the same compound. Mass spectrometry analysis 
sometimes showed the appearance of dimers though this data is anecdotal and was not found 
consistently for each molecule. Furthermore, none of these ligands were observed in the 
HRMS spectra. 
These catalysts were not analysed by NMR due to the palladium caused a broadening of the 
spectrum making it difficult to identify individual peaks. Thus, the structure of the Pd centre 
is yet to be confirmed. Ideally X-ray crystallography would be the best way to determine the 
structure and confirm that it is the oxygen atom from the amide bond coordinating and not the 
nitrogen (NMR confirmation of the presence of an enol would also support this if possible). 
However, yields of the compound during this this were not significant enough to begin the 
process of attempting crystallisation. Other form of spectroscopy such as UV or IR might also 
provide information about the nature of the bonding within the molecule (anecdotally it is 
known that the Pd-loaded catalysts absorb more at 282 nm). ICP is useful for determining the 
presence and levels of palladium, however this gives no structure insights. Revisiting the mass 
spectrometry and different techniques available there and designing experiments to probe the 
ligand structure may be one of the best initial routes. 
Some of these structures have been published with equivalent amounts of data, however this 




the structure of the Pd as in all the papers in which the structure has been published, none make 
an attempt to confirm it with structural techniques. 
3-[2-[(5-Carboxypentyl)amino]-2-oxoethyl]-1-(2-pyridinylmethyl)-1H-imidazol-2-
ydiene palladium(II) 10 
 
Synthesised from 8. The product was isolated as a white solid (14 mg, 32.2 µmol, 11 %). 
Purity by HPLC: 94 %; HRMS (ESI) calculated 435.0629 for C17H21O3N4106Pd; found 





Synthesised from 33. The product was isolated as a white solid (9 mg, 23.7 µmol, 8 %). 
Purity by HPLC: 94 %; HRMS (ESI) calculated 379.0017 for C13H13O3N4106Pd; found 







ydiene palladium(II) 12 
 
Synthesised from 34. The product was isolated as a white solid (10 mg, 24.6 µmol, 8 %). 
Purity by HPLC: 90 %; HRMS (ESI) calculated 407.0323 for C15H17O3N4106Pd; found 
407.0332 [M+H]+; HPLC tR 1.8 min (254 nm).  
 
3-[2-[(7-Carboxyheptyl)amino]-2-oxoethyl]-1-(2-pyridinylmethyl)-1H-imidazol-2-
ydiene palladium(II) 13 
 
Synthesised from 35. The product was isolated as a white solid (13 mg, 28.0 µmol, 9 %). 
Purity by HPLC: 82 %; HRMS (ESI) calculated 463.0956 for C19H25O3N4106Pd; found; 








ydiene palladium(II) 14 
 
Synthesised from 36. The product was isolated as a white solid (17 mg, 40.4 µmol, 13 %). 
Purity by HPLC: 93 %; HRMS (ESI) calculated 421.0486 for C16H19O3N4106Pd; found 





Synthesised from 37. The product was isolated as a white solid (15 mg, 32.0 µmol, 11 %). 
Purity by HPLC: 94 %; HRMS (ESI) calculated 469.0486 for C20H19O3N4106Pd; found 











Synthesised from 38. The product was isolated as a white solid (10 mg, 22.2 µmol, 7 %). 
Purity by HPLC: 95 %; HRMS (ESI) calculated 450.0752 for C17H22O3N5106Pd; found 
450.0750 [M+H]+; HPLC tR 1.1 min (254 nm).  
 
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazol-2-ydiene-3-yl]acetyl]-L-phenylalanyl-L-
tryptophan-5-carboxypentylic acid palladium(II) 17 
 
Synthesised from 39. The product was isolated as a white solid (21 mg, 27.3 µmol, 7 %). 
Purity by HPLC: 96 %; HRMS (ESI) calculated 768.2120 for C37H40O5N7106Pd; found; 






valine-L-glycine palladium(II) 18 
 
Synthesised from 40. The product was isolated as a white solid (18 mg, 28.0 µmol, 14 %). 
Purity: 96 %; HRMS ESI-MS calculated 624.1545 for C27H32O4N7106Pd; found 624.1556 
[M+H]+; HPLC; tR 3.5 min (254 nm).  
 
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazol-2-ydiene-3-yl]acetyl]-L-valine-(5-
carboxypentyl)-L-lysine(azide) amide palladium(II) 19 
 
Synthesised from 41. The product was isolated as a white solid (25 mg, 36.4 µmol, 18 %). 
Purity by HPLC: 95 %; HRMS ESI-MS calculated 687.2342 for C28H41O4N10106Pd; found 







carboxypentyl)-L-glutamaic acid amide palladium(II) 20 
 
 
Synthesised from 42. The product was isolated as a white solid (29 mg, 42.8 µmol, 22 %). 
Purity by HPLC: 97 %; HRMS ESI-MS calculated 662.1913 for C27H38O6N7106Pd; found 
662.1932 [M+H]+; HPLC; tR 2.6 min (254 nm).  
 
N-[2-[1-(2-Pyridinylmethyl)-1H-imidazol-2-ydiene-3-yl]acetyl]-L-valine-(5-
carboxypentyl)-L-lysine amide palladium(II) 21 
 
Synthesised from 43. The product was isolated as a white solid 18 mg (27.2 µmol, 13 %). 
Purity by HPLC: 96 %; HRMS ESI-MS calculated 661.2437 for C28H43O4N8106Pd; found 






5.4 Protein conjugation experiments 
Analysis by absorbance measurements 
The degree of labelling for protein-fluorophore conjugates was calculated using the equations 
described in Chapter 3 (repeated below). In all cases a dilution factor of 10 was used, and the 
correction factor for fluorescein was 0.3. The wavelength for Amax was 492 nm. ε vales for 
BSA, Herceptin and fluorescein were 43,824 cm-1 M-1 (AAT bioquest), 210,000 cm-1 M-1 
(Thermofisher tech tip #31), 68,000 cm-1 M-1 (Thermofisher tech tip #31) respectively. 
(3.1) 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀) =  
𝐴280 − (𝐴𝑚𝑎𝑥 × 𝐶𝐹)
𝜀
 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Equation 3.1. Equation used to calculate the protein concentration after conjugation with a fluorophore. 
Where A280 is the absorbance at 280 nm of the protein-fluorophore conjugate. Amax is the absorbance 
value at the maximum absorbance wavelength of the fluorophore (for example FAM = 492 nm). CF is 
the correction factor (correcting for the absorbance of the fluorophore at 280 nm). ε is the molar 
extinction coefficient of the protein and the dilution factor is any dilution applied to the sample. 
(3.2) 𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑑𝑦𝑒 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 =
𝐴𝑚𝑎𝑥  𝑜𝑓 𝑡ℎ𝑒 𝑙𝑎𝑏𝑒𝑙𝑙𝑒𝑑 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝜀′ × 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [𝑀]
× 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Equation 3.2. Equation to calculate the degree of labelling from using equation 3.1. “Amax of the 
labelled protein” is the absorbance value at the maximum absorbance wavelength of the fluorophore; ε' 
is the molar extinction coefficient of the fluorophore; protein concentration [M] is found from Equation 
3.1.; Dilution factor is any dilution that may have been applied to the sample. 
Analysis of proteins by SDS-PAGE 
Protein samples (1 mg/ml, 10 µl) were diluted with 2 × sample buffer (10 µl) and heated to 95 
°C for 5 min. The samples were then loaded into a precast 10 % poly acrylamide gel and run 
at 80 V (30 min) followed by 160 V (90 min). The gel was submerged in Coomassie staining 
solution (~100 mL) for 4 h and then de-stained for 24 h (de-staining solution (100 mL) 
replaced every 6 h). The gel was then viewed under white light in a GelDoc imaging system 
and analysed on Image Lab software. 
Analysis by MALDI-TOF MS 
The spectra of protein conjugate products were compared to native Herceptin. 2,5-




MADLI-TOF was analysed in positive mode. The difference in mass between the highest 
intensity peaks was determined and then divided by the molecular weight of the molecule 
added to get a degree of labelling by MALDI-TOF MS. 
Analysis by ICP-MS 
For ICP-MS analysis (Pd content), Pd-antibody conjugates (1 µl) was added to concentrated 
nitric acid (75 µL). The resulting solution was diluted to 5 % HNO3 with water (1.5 mL), and 
Pd analysis was carried out by ICP-MS with calibration against Pd standard solutions (n = 3). 
The Pd content per antibody was quantified using the two equations below. 
(5.1)
[𝑝𝑝𝑚]
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑙𝑙𝑎𝑑𝑖𝑢𝑚 
 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 = 𝑚𝑜𝑙𝑒 𝑜𝑓 𝑃𝑑 𝑝𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑒 




= 𝑚𝑜𝑙𝑒 𝑃𝑑 𝑝𝑒𝑟 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 
Sample calculation using data for compound 30a 
(4.22 [
𝑚𝑔









]  × 1.5 𝑚𝐿 = 3.32 𝑚𝑔 𝑜𝑓 𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦 
119.4 𝑛𝑚𝑜𝑙
6.63 𝑚𝑔
= 18.6 𝑛𝑚𝑜𝑙 𝑜𝑓 𝑃𝑑/𝑚𝑔 𝑜𝑓𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦 
Alternatively, the Pd content can be calculated by as follows: 
(5.1)
[𝑝𝑝𝑚]
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑙𝑙𝑎𝑑𝑖𝑢𝑚 



































= 15.2 µM of antibody 
39.8 [µM]
15.2 [µM]
= 2.6 𝑚𝑜𝑙 𝑜𝑓 𝑃𝑑 𝑝𝑒𝑟 𝑚𝑜𝑙 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 
 
5(6)-Carboxyfluorescein BSA 25a 
 
BSA (5 mg) was dissolved in PBS (250 µL, pH 7.0) and a solution of 5(6)-carboxyfluorescein-
NHS (11 µL, 10 mg/mL) was added. The solution was shaken at 37 °C for 4 h in an Eppendorf 
ThermoMixer®. The solution was diluted in PBS (200 µL) and purified using Amicon 
centrifugal spin columns (0.5 mL, MWCO 10 kDa) using a Thermo Scientific Heraeus Pico 
17 benchtop centrifuge (13200 rpm, 10 min) and washed with PBS (10 × 0.5 mL) to elute 
unreacted carboxyfluorescein-NHS. The concentrated protein solution (50 µL) was collected 
in an Eppendorf tube by centrifugation (1 min, 13200 rpm). 
SDS-PAGE: Broad band at 66,000 Da; MALDI-TOF MS: Intensity max at 66,600 Da; 
Absorbance: 0.94 at 280 nm, 1.42 at 492 nm; Degree of labelling: 1.8 moles of fluorophore 




5(6)-Carboxyfluorescein BSA 25b 
 
25b was synthesised using the same methodology as 25a except using pH 8.0.  
SDS-PAGE: Broad band at 67,000 Da; MALDI-TOF MS: Intensity max at 67,200 Da; 
Absorbance: 0.87 at 280 nm, 1.87 at 492 nm; Degree of labelling: 3.9 moles of fluorophore 
per mole of BSA.  
BSA-dibenzocyclooctyne 26 
 
BSA (5 mg) was dissolved in PBS (250 µL, pH 7.0) and a solution of DBCO-NHS dissolved 
in DMSO (30.8 µL, 5 mg/mL) was added. The solution was shaken at 37 °C for 4 h in an 
Eppendorf ThermoMixer®. The solution was diluted in PBS (200 µL) and purified with 
Amicon centrifugal spin columns (0.5 mL, MWCO 10 kDa) using a Thermo Scientific 
Heraeus Pico 17 benchtop centrifuge (13200 rpm, 10 min) and washed with PBS (10 × 0.5 
mL) to elute unreacted DBCO-NHS. The concentrated protein solution (50 µL) was collected 




SDS-PAGE: Band at 67,000 Da; MALDI-TOF MS: Intensity max at 67,200 Da; Degree of 
labelling: 4 moles of DBCO per mole of BSA.  
 
BSA-dibenzocyclooctyne-fluorescein azide 27 
 
To 26 (45 µL, 20 mg/mL) a solution of 5-carboxyfluorescein-azide dissolved in PBS (169 µL, 
1 mg/mL) was added. The solution was shaken at 37 °C for 4 h in an Eppendorf 
ThermoMixer®. The solution was diluted in PBS (200 µL) and purified using Amicon 
centrifugal spin columns (0.5 mL, MWCO 10 kDa) using a Thermo Scientific Heraeus Pico 
17 benchtop centrifuge (13200 rpm, 10 min) and washed with PBS (10 × 0.5 mL) to elute 
unreacted 5-carboxyfluorescein azide. The concentrated protein solution (50 µL) was collected 
in an Eppendorf tube by centrifugation (1 min, 13200 rpm).  
SDS-PAGE: Broad band at 66,000 Da; MALDI-TOF MS: Intensity max at 68,400 Da; 
Absorbance: 0.8 at 280 nm, 1.51 at 492 nm; Degree of labelling: 2.8 moles of fluorophore 
per mole of BSA.  
 





To Herceptin (50 µL, 20 mg/mL), PBS (150 µL) was added. To this a solution of DBCO-NHS 
dissolved in DMSO (2.79 µL, 5 mg/mL, 5 eq.) was added. The solution was shaken at 37 °C 
for 4 h in an Eppendorf ThermoMixer®. The solution was diluted in PBS (200 µL) and purified 
using Amicon centrifugal spin columns (0.5 mL, MWCO 10 kDa) using a Thermo Scientific 
Heraeus Pico 17 benchtop centrifuge (13200 rpm, 10 min) and washed with PBS (10 × 0.5 
mL) to elute unreacted DBCO-NHS. The concentrated protein solution (50 µL) was collected 
in an Eppendorf by centrifugation (1 min, 13200 rpm).  
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 146,000 







To 28a (45 µL, 20 mg/mL), a solution of 5-carboxyfluorescein-azide (15.8 µL, 1 mg/mL, 5 
eq.) was added. The solution was shaken at 37 °C for 4 h in an Eppendorf ThermoMixer® C. 
The solution was diluted in PBS (200 µL) and purified using Amicon centrifugal spin columns 
(0.5 mL, MWCO 10 kDa) using a Thermo Scientific Heraeus Pico 17 benchtop centrifuge 
(13200 rpm, 10 min) and washed with PBS (10 × 0.5 mL) to elute unreacted DBCO-NHS. The 
concentrated protein solution (50 µL) was collected in an Eppendorf by centrifugation (1 min, 
13200 rpm). 
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 147,000 
Da; Absorbance: 1.41 at 280 nm, 0.97 at 492 nm; Degree of labelling: 2.8 moles of 




To 28a (45 µL, 20 mg/mL), a solution of 19 (3.45 µL,10 mM) was added. The solution was 
shaken at 37 °C for 4 h at 1000 rpm in an Eppendorf ThermoMixer®. The solution was diluted 
in PBS (200 µL) and purified using Amicon centrifugal spin columns (0.5 mL, MWCO 10 
kDa) using a Thermo Scientific Heraeus Pico 17 benchtop centrifuge (13200 rpm, 10 min) and 
washed with PBS (10 × 0.5 mL) to elute unreacted 19. The concentrated protein solution (50 




SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 148,000 
Da; ICP-MS: 4.22 ppm (15.2 µM); Degree of labelling: 2.7 moles of Palladium per mole of 
Herceptin. 
Herceptin-dibenzocyclooctyne, high loading (28b) 
 
For 28b the reaction was repeated using the same conditions as those used to make 28a but 
with a larger quantity of DBCO-NHS dissolved in DMSO (154 µL, 5 mg/mL, 25 eq.).  
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 148,000 






For 30b the rection was repeated using the same conditions as compound 30a except using 
28b as a starting molecule and higher quantities of 19 (17.3 µL, 10 mM).  
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 155,000 





To Herceptin (50 µL, 20 mg/mL), PBS (150 µL) was added. To this a solution of DBCO-
(Peg)12-NHS dissolved in PBS (3.4 µL, 10 mg/mL) was added.  
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 147,000 




31b was synthesised using the same protocol as 31a except using a larger amount of DBCO-




SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 154,000 




To 31a (45 µL, 20 mg/mL), a solution of 19 (3.45 µL,10 mM) was added. The solution was 
shaken at 37 °C for 4 h at 1000 rpm in an Eppendorf ThermoMixer®. The solution was diluted 
in PBS (200 µL) and purified using Amicon centrifugal spin columns (0.5 mL, MWCO 10 
kDa) using a Thermo Scientific Heraeus Pico 17 benchtop centrifuge (13200 rpm, 10 min) and 
washed with PBS (10 × 0.5 mL) to elute unreacted 19. The concentrated protein solution (50 
µL) was collected in an Eppendorf by centrifugation (1 min, 13200 rpm). 
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 148,000 








32b was synthesised using the same protocol as use to synthesis 32a except starting using 31b 
as a starting molecule with a larger amount of 19 (17.3 µL,10 mM).  
SDS-PAGE: Bands at 25,000 and 50,000 Da; MALDI-TOF MS: Intensity max at 165,000 







5.5 Biological experiments 
Kinetic assays of fluorophore activation 
Catalyst screening: Stock solutions (20 µM) of the probe dichlorofluorescein were prepared 
in 5 % acetonitrile with either PBS or plasma. The catalyst solutions were freshly prepared 
either in PBS or in plasma. The screenings were carried out on black 96-well plates. 50 µL of 
the probe Pro-DCF or PROC-Rh 110 (to give a working concentration of 10 µM) was added 
per well, followed by 50 µL of the catalyst solution (0.8 mol %) and the increase in 
fluorescence (λex/em = 485/520 nm) at 37 °C recorded over time (4 h or 12 h) on a plate reader 
(n = 3). The relative increase in fluorescence was compared with the blank and the control 
experiment (PBS or plasma).  
Stability of catalysts  
Catalysts 8, 9 and 12 (~1 mg/mL) were stored in H2O/ACN (9:1) at 4 °C for 2 months. 
Following this, the samples were analysed by analytical HPLC.   
Cell culture 
HeLa, SK BR-3 or MCF-7 cells were cultured in Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS), L-glutamine (4 mM) and antibiotics 
(penicillin and streptomycin, 100 units/mL). Cell culture was performed in a 5 % CO2 
atmosphere at 37 °C in 1377 Experimental a SteriCult 200 (Hucoa-Erloss) incubator. The day 
before the assays, the cells were washed with PBS, detached with 
trypsin/ethylenediaminetetraacetic acid (EDTA) (0.25 % trypsin, 1 mM EDTA), counted, and 
diluted with DMEM to the appropriate concentration. 
Prodrug activation in MCF-7 cells  
carried out by Durgadas Cherukaraveedu 
MCF-7 cells (from the European Collection of Authenticated Cell Cultures (ECACC)) were 
grown in Dulbecco’s modified eagle medium (DMEM) supplemented with 10 % FBS, 1 % 
penicillin/streptomycin and 200 nM L-glutamine in a humidified incubator at 37 °C with 5 % 
CO2. Cells were cultured in T-75 flasks (Corning) to ≥ 80 % confluence. Cells were harvested 
with trypsin/EDTA (Gibco.) The MCF-7 cells (8 × 103 cells/well) were seeded on 96-well 
plates and grown to ~60 % confluence overnight. Control cells were treated with 100 µM of 
5-FU (with 1 % DMSO), 100 µM Pro-5-FU (with 1 % DMSO), and 10 µM and 50 µM of 




day and followed by addition of 10 mol % (Pd) of catalyst 8, and the cells were incubated for 
4 days under standard cell culture conditions. The cells were washed with PBS, followed by 
the addition of 100 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) solution (1 mg/mL in PBS/DMEM, 3:7, v/v) for 3 h at 37 °C. Then, 100 µL of MTT 
solubilisation solution (10 % Triton-X 100 in 0.1 N HCI in isopropanol) was added to each 
well and the plate was shaken horizontally for 30 min to dissolve the formazan crystals. The 
absorbance at 570 nm was measured on a multimode plate reader and the cell viability was 
calculated compared to untreated cells and expressed as percentage of cell viability. 
Prodrug activation in MCF-7 spheroids  
carried out by Durgadas Cherukaraveedu 
MCF-7 cells (ECACC) were added into black 96-well Corning Ultra low attachment surface 
coated microplates (~2000 cells/well) to generate the multicellular spheroids. The media was 
changed daily until spheroids formed (approximately 750 µm diameter). The spheroids were 
treated with 100 µM of Pro-5-FU and 10 mol % of the catalyst 8 on the well plate, and 
incubated for 4 days. The control spheroids were treated with catalyst 8 (10 mol %), or 5-FU 
(100 µM) or Pro-5-FU (100 µM). The spheroids were washed thoroughly with PBS and 
stained for cell viability with the LIVE/DEAD™ Cell Imaging Kit (488/570) according to 
manufacturer’s instructions and imaged with a confocal microscope. 
Cell viability assay 
HeLa cells were plated in a 96-well plate (10000 cells/well) and grown for 24 h. Solutions of 
19, 20, 21 and PROC-Rh 110 in DMEM were added to the wells at the desired concentrations 
and incubated with the cells for 24 h. Media was then replaced with 350 µL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (1 mg/mL) and the 
cells incubated for 3 h at 37 °C. After incubation, the resulting formazan crystals were 
dissolved by adding 350 µL of MTT solubilisation solution (10 % Triton-X 100 in 0.1 N HCl 
in isopropanol). The absorbance was measured at a wavelength of 570 nm (BioTek HT 
Synergy multi-mode reader) and results compared to a control of untreated cells which were 
normalised to 100 %.  
Flow cytometry 
For flow cytometry analysis, SKBR-3 and MCF-7 cells were plated in a 24-wellplate (20000 
cells/well) and grown for 24 h at 37 °C. The medium was removed and a solution of 30a (at 




incubation, cells were washed twice with PBS, harvested with trypsin/EDTA (0.25 % trypsin, 
1 mM EDTA) and resuspended in DMEM. Intracellular fluorescence was analysed by flow 
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Solid-phase synthesis of biocompatible
N-heterocyclic carbene–Pd catalysts using a
sub-monomer approach†
Durgadas Cherukaraveedu, ‡ Paul T. Cowling, ‡ Gavin P. Birch,
Mark Bradley * and Annamaria Lilienkampf *
Taking inspiration from the assembly of so-called peptoids (N-alkylglycine oligomers) we present a new
synthetic methodology whereby N-heterocyclic carbene (NHC) based Pd ligands were assembled using a
sub-monomer approach and loaded with Pd via solid-phase synthesis. This allowed the rapid generation a
library of NHC–palladium catalysts that were readily functionalised to allow bioconjugation. These catalysts
were able to rapidly activate a caged fluorophore and ‘switch-on’ an anticancer prodrug in 3D cell culture.
Introduction
Bioorthogonal reactions enable the selective visualisation and
manipulation of biological processes in living systems and
have been widely used in a number of applications.1–4
Transition metal mediated bioorthogonal reactions are of par-
ticular interest as they enable an array of non-natural chemical
transformations that can be used to modulate living
systems.5,6 Reactions mediated by copper,7,8 iron,9 gold,10–12
ruthenium,12–16 and iridium17 have all found applications in
living systems, although palladium is perhaps the most uti-
lised metal in a biological setting.18
Palladium has gained popularity in bioorthogonal chem-
istry due its ability to perform catalytic cross-coupling reac-
tions, enabling the generation of carbon–carbon and carbon–
heteroatom bonds under mild, biological conditions,19–21 and
more recently in vivo.22,23 Palladium catalysts have been used
to initiate a range of intracellular reactions including dealkyla-
tion,24 decaging of propargyloxycarbonyl groups,19,24,25 as well
as Suzuki–Miyaura cross-couplings.20,26–28 Thus, palladium
mediated reactions have been used to selectively activate
enzymes through deprotection of modified amino acids within
proteins,21,29 to synthesise anticancer agents in cellulo from
two benign precursors,19 as well as activate produgs;20–22,24
however, to date, the majority of the examples have used
palladium nanoparticles entrapped within a polymeric
support,19,20,22–24,26,27,30 simple palladium salts such as
Pd(OAc)2,
31–33 or designed targeted palladium ligands.34
This is in contrast to the highly active palladium catalysts
used in conventional organic synthesis that use a variety of sta-
bilising ligands (e.g. phosphines) or N-heterocyclic carbenes
(NHC),35,36 but few have been used in a biological setting.
Chen used an NHC–Pd catalyst (with imidazolium-based
ligands bearing hydrophilic quaternary ammonium salts) to
mediate the Suzuki–Miyaura coupling reaction between a
boronic acid functionalised biotin and 4-iodophenylalanine
modified cell surface proteins, enabling subsequent imaging
of the cell surface with fluorescently labelled streptavidin.33
Recently, we reported a water soluble NHC–Pd catalyst coupled
to a cell penetrating peptide, which was able to remove a pro-
pargyloxycarbonyl group from a pro-fluorophore in cells, thus
demonstrating the first intracellular application of NHC–Pd
chemistry.37 While catalyst loading was carried out on the
solid-phase, the synthesis of the NHC ligand required multi-
step synthesis in solution, purification, and conjugation to a
solid support.
Here, we report an efficient microwave assisted solid-phase
synthesis of a series of biocompatible NHC–Pd catalysts and
their chemistry in cells. To the best of our knowledge, a solid
phase approach to the generation of NHC–Pd catalysts has not
been reported and, with our approach, these stable NHC–Pd
catalysts were prepared in good yields with the majority of the
catalysts showing good activity in a biological setting.
Results and discussion
A solid-phase synthetic route was developed for the NHC–Pd
catalysts by adopting the ‘sub-monomer’ approach, originally
developed by Zuckermann for the synthesis of peptoids
(N-alkyl glycine oligomers), with sequential acylation and alkyl-
ation reactions on a resin.38,39 The NHC ligand chosen here
†Electronic supplementary information (ESI) available: Supporting figures and
tables, and experimental procedures. See DOI: 10.1039/c9ob00716d
‡Equal contribution.
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was first reported by Meldal who showed that a resin-bound
NHC–Pd complex (conjugated to a hydrophobic dipeptide)
showed good catalytic efficiency in Suzuki–Miyaura cross-coup-
lings in water.40 Here, this pyridine-derivatised imidazolium
ligand was attached to a range of different amino acid spacers,
with the aim of providing biocompatibility, aqueous stability,
as well as a handle for biomolecule conjugation.
Solid-phase synthetic route for the NHC–Pd catalysts
Fmoc-Ahx-OH was coupled to a 2-chlorotrityl chloride linker
on a polystyrene resin (mesh 100–200), with subsequent
removal of the Fmoc group giving 1, which was acylated with
2-bromoacetic acid (2 M in DMF) using DIC as a coupling
reagent at 60 °C under μw irradiation for 20 min (Scheme 1).
The bromide in 2 was substituted by imidazole to give 3, with
optimised reaction conditions (ESI, Table S1†) allowing quanti-
tative N-alkylation via an excess of imidazole (2 M) at 60 °C (μw
heating for 40 min) in anhydrous DMSO with 0.5 M AgNO3.
The addition of AgNO3 was required for full conversion (based
on HPLC analysis, ESI, Fig. S1†). The imidazole in 3 was
N-alkylated with 2-(bromomethyl)pyridine (1 M) to give 4 with
>95% conversion using Et3N (1 M) and AgNO3 (0.5 M) at 60 °C
in anhydrous DMF (for optimisation see ESI, Table S2†) giving
the NHC ligand in >95% purity and 65% overall yield over 3
steps (ESI, Fig. S2 and S3†). Palladium loading of the NHC-
ligand 4 on solid-phase was carried out as reported by
Meldal40 with minor modifications. In brief, the carbene was
generated on the resin from the imidazolium ion with the
phosphazene base 2-tert-butylimino-2-diethylamino-1,3-di-
methylperhydro-1,3,2-diazaphosphorine (BEMP) in anhydrous
DMF. Pd(COD)Cl2 was added subsequently to generate the
NHC–Pd catalyst 5 (Scheme 1), which was cleaved off the resin
with 30% HFIP in DCM and purified by semi-preparative
RP-HPLC. This allowed the rapid and efficient generation of
>100 mg quantities of the catalyst 5 that could be freely
stored.§
Synthesis of NHC–Pd catalyst library
This solid-phase synthesis route was used to generate an
NHC–Pd catalyst library (5–12). Using the NHC moiety with
different amino acid spacers gave a range of both hydrophilic
and hydrophobic groups to compare the potential effect on
catalytic activity, as well as the robustness of the synthetic
method (Fig. 1). The catalysts were synthesised using the
2-chlorotrityl linker, but the methodology was also compatible
with the Rink-amide linker (ESI, catalyst 13). The ligands for
catalysts 5–12 were fully characterised using NMR, HPLC, and
HRMS, and after palladium loading, the catalysts were cleaved
off the resin, purified by semi-preparative RP-HPLC, and
characterised by ESI-MS and HPLC (ESI, Table S3†). The purity
of the catalysts was confirmed by analytical HPLC (ESI, Fig. S4
and S5† – the “naked ligands” and the Pd-loaded ligands dis-
played different retention times) and the presence of palla-
Scheme 1 The microwave assisted solid-phase synthesis of NHC–Pd catalyst 5. (a) 0.3 M Fmoc-Ahx-OH, 0.5 M DIPEA, anhydrous DCM–DMF (9 : 1),
1 h; (b) 20% piperidine in DMF, 2 × 10 min; (c) 2 M BrCH2CO2H, 1 M DIC, anhydrous DMF, 20 min, 60 °C, μw; (d) 2 M imidazole, 0.5 M AgNO3 in anhy-
drous DMSO, 40 min, 60 °C, μw; (e) 1 M 2-(bromomethyl)pyridine, 1 M EtN3, 0.5 M AgNO3, anhydrous DMF, 90 min, 60 °C, μw; (f ) BEMP, anhydrous
DMF, N2, 45 min, then Pd(COD)Cl2 overnight; (g) 30% HFIP–DCM, 1 h. All conversions were monitored by cleavage of a small sample from the resin
and characterisation by HPLC and NMR. As drawn, the catalyst is Pd(II) with Y most likely formate (from the HPLC purification buffer).
§The solid-phase approach used here offers advantages over more traditional
solution-phase methods, namely the use of mass-action to drive the chemistries
and the removal of intermediary purification steps. The ligand was previously
synthesised in three steps (in solution) with a combined reaction time of 7.5 h
(compared to 3 h in this work) requiring both silica column chromatography
and preparative RP-HPLC purification.40
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dium also established by HRMS (ESI, Fig. S6†) (the presence of
the Pd meant that the 1H NMR spectra were highly broad-
ened). These catalysts were stable for two weeks at room temp-
erature in ACN/H2O, and ≥8 weeks at 4 °C.
Screening of catalytic activity
The fluorogenic probe based on 2,7-dichlorofluorescein (DCF)
was used to evaluate the activity of the catalysts.41 The pro-
fluorophore O-propargylated DCF-1 was converted to the fluo-
rescent molecule DCF-2 (λEx/Em 480/520 nm) upon Pd-catalysed
cleavage of the propargyl group (Fig. 2A). Catalyst screening
was carried out at 37 °C in PBS and in MCF-7 cell lysate to
evaluate catalytic activity under biologically relevant con-
ditions. Catalysts 5–12 (0.8 mol%) were incubated with DCF-1
(10 μM) and the increase in fluorescence measured over 4 h
with an additional measurement at 20 h (ESI, Fig. S7†). With
the exception of 7 and 11, all the catalysts were active in PBS
with 8 and 9 showing comparable activity to 0.8 mol%
Pd(OAc)2 (Fig. 2B). The decaging reactions were notably slower
in cell lysate with 8 and 9 again showing the best catalytic
efficiency under these conditions and outperforming Pd(OAc)2
(ESI, Fig. S8A†). Although shorter hydrophobic spacers seemed
to be preferred in PBS (8 > 9 > 10), clear structure–activity
relationships could not be established for the catalytic activity,
particularly in the cell lysate, highlighting the need for
methods to rapidly generate combinatorial catalyst libraries.
Catalyst 8 was further evaluated by monitoring the decaging
of DCF-1 (50 µM) by HPLC, with the experiments performed in
PBS and in human plasma to mirror a cellular environment
rich in proteins. In PBS, 8 (2 mol%) gave 92% conversion to
DCF-2 after 5 h (Fig. 2C), whereas in plasma 97% conversion
was observed (ESI, Fig. S8B†).
Prodrug activation in cancer cells and in cancer cell spheroids
The catalyst 8 was evaluated for its efficiency to activate the
caged anticancer drug N-propargyl protected 5-fluorouracil24
(Pro-5-FU) (Fig. 3A). In PBS, 5 mol% of 8 was able to convert
Pro-5-FU (100 µM) into the active drug 5-fluorouracil (5-FU)
within 48 h, as monitored by HPLC (Fig. 3B).
The co-treatment of MCF-7 cell first with Pro-5-FU (100 µM)
for 24 h followed by catalyst 8 (10 mol%) for 4 days resulted in
Fig. 1 The NHC–Pd catalysts 5–12 synthesised by the optimised solid-
phase synthesis protocol (Scheme 1). As drawn, the catalyst is Pd(II). In
the biological experiments Y can be exchanged to various species with
different coordination/charge states possible.
Fig. 2 (A) Pd catalysed depropargylation reaction of profluorophore
DCF-1 to give fluorescent DCF-2 (λEx/Em 480/520 nm). (B) Screening of
catalysts 5–12 (0.8 mol%) for the activation of DCF-1 (10 µM) in PBS
(n = 3). The reactions were monitored over 4 h and the increase in fluor-
escence recorded over time and compared to blank (no catalyst) and
0.8 mol% Pd(OAc)2. (C) The catalytic decaging of DCF-1 (50 µM) with
catalyst 8 (2 mol%) monitored by HPLC (detection at 282 nm) over 5 h
with the reaction carried out in PBS, showing >92% of DCF-2.
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comparable cytotoxicity (MTT assay) to 5-FU (Fig. 3C), with the
drug activation likely taking place both intra- and extracellu-
larly (Pro-5-FU is readily taken up by cells30). Catalyst 8 did not
show notable cytotoxicity with 84% cell viability at 10 µM
concentration.
Next, MCF-7 spheroids were treated with the prodrug Pro-5-
FU (100 µM) and catalyst 8 (10 mol%) for 5 days, stained with
the LIVE/DEAD™ Cell Imaging Kit (488/570), and analysed by
fluorescence microscopy. Spheroids treated with both the
prodrug and catalyst resulted in cell death comparable to cells
treated with 5-FU, whereas treatment with only the catalyst or
the prodrug Pro-5-FU had no effect on the viability of the 3D
spheroids (Fig. 3D). These results demonstrate that the catalyst
was able to decage a protected prodrug in a more representa-
tive 3D cancer model, which may have applications in future
anticancer prodrug therapies.
Conclusions
A highly efficient microwave assisted solid-phase synthesis of
NHC–Pd catalysts, based on the ‘sub monomer’ approach was
developed and used to generate biocompatible catalysts on
scale. Catalyst 8, comprising of the NHC–Pd moiety linked to a
glycine, was the most robust catalyst in the series and was able
to activate a fluorogenic probe in a biological setting and decage
the protected anticancer drug (5-fluoro-1-propalgyluracil) in a 3D
cancer cell culture resulting in comparable cell death to 5-fluoro-
uracil. These robust NHC-Pd catalysts have a carboxylic acid that
can be readily converted to a stable active ester thus providing a
handle for bioconjugation and offering applications for both
specific cell targeting ligands and bioorthogonal prodrug
activations.
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Fig. 3 (A) The Pd-catalysed decaging of prodrug 5-fluoro-1-propargyluracil Pro-5-FU into the active anticancer drug 5-fluorouracil 5-FU. (B)
Decaging of Pro-5-FU (100 µM) with catalyst 8 (5 mol%) in PBS (pH 7.4, 37 °C) monitored by HPLC with detection at 282 nm. (C) MTT cytotoxicity
assay for prodrug activation in MCF-7 cells. The prodrug Pro-5-FU (100 μM with 1% DMSO) did not induce cytotoxicity and the NHC–Pd catalyst 8
(10 µM) only showed minor reduction in cell viability (84% viability) after 5 days incubation (untreated control cells were defined as 100% viable). Co-
treatment with catalyst 8 (10 mol%, 10 µM) and Pro-5-FU (100 µM) for 5 days resulted in comparable cytotoxicity to 5-FU. (D) In situ activation of
prodrug Pro-5-FU by catalyst 8 in 3D MCF-7 spheroids (drug activation most likely happening extracellularly). The spheroids were imaged for live/
dead status, Green cells (λEx/Em 495/520 nm) are live whilst the red cells (λEx/Em 595/615 nm) are dead. (i) Untreated spheroid (control); (ii) Spheroid
treated with (10 µM) of catalyst 8; (iii) Spheroid treated with 5-FU (100 µM) resulting in cell death; (iv) Spheroid treated with prodrug Pro-5-FU
(100 µM) showing good viability; (v) Spheroid co-treated with the Pro-5-FU (100 µM) and catalyst 8 (10 µM) suggesting cell death equivalent to that
seen with 100 µM of 5-FU. Scale bar 100 μm.
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